Chemotherapy agents - AntiMetabolites: All cancers

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**23716**	**100**	**0.4**	**279**	**1.2**	**6277**	**26.7**	**45**	**0.2**
	Age at baseline	<18	5295	12	0.2	80	1.5	1664	31.7	16	0.3
		18-19	1964	8	0.4	33	1.7	569	29.3	1	0.1
		20-24	5511	28	0.5	65	1.2	1480	27.1	9	0.2
		25-29	5150	28	0.5	47	0.9	1349	26.5	8	0.2
		30-34	3566	15	0.4	30	0.9	823	23.4	8	0.2
		35+	2230	9	0.4	24	1.1	392	17.9	3	0.1
	Years since diagnosis	5-9	2391	3	0.1	33	1.4	780	33.1	4	0.2
		10-14	7681	29	0.4	93	1.2	2186	28.7	20	0.3
		15-19	7592	40	0.5	88	1.2	1922	25.6	16	0.2
		20+	6052	28	0.5	65	1.1	1389	23.2	5	0.1
	Age at diagnosis	<1	1789	1	0.1	31	1.7	235	13.2	7	0.4
		1-4	7646	31	0.4	114	1.5	2420	31.9	11	0.1
		5-9	5313	32	0.6	42	0.8	1546	29.4	7	0.1
		10-14	5026	24	0.5	62	1.2	1345	27.0	10	0.2
		15-20	3942	12	0.3	30	0.8	731	18.8	10	0.3
Males	**All cases**		**12555**	**48**	**0.4**	**120**	**1.0**	**3527**	**28.4**	**23**	**0.2**
	Age at baseline	<18	2844	7	0.2	35	1.2	926	32.9	6	0.2
		18-19	1013	3	0.3	15	1.5	318	31.7	1	0.1
		20-24	2866	12	0.4	25	0.9	782	27.5	3	0.1
		25-29	2820	16	0.6	20	0.7	790	28.3	5	0.2
		30-34	1889	8	0.4	14	0.7	489	26.2	6	0.3
		35+	1123	2	0.2	11	1.0	222	20.1	2	0.2
	Years since diagnosis	5-9	1331	3	0.2	13	1.0	461	35.2	1	0.1
		10-14	4084	11	0.3	45	1.1	1222	30.2	11	0.3
		15-19	3944	23	0.6	32	0.8	1045	26.8	7	0.2
		20+	3196	11	0.3	30	0.9	799	25.3	4	0.1
	Age at diagnosis	<1	907	1	0.1	13	1.4	108	12.0	2	0.2
		1-4	3967	15	0.4	53	1.3	1325	33.7	5	0.1
		5-9	2975	16	0.5	16	0.5	900	30.6	4	0.1
		10-14	2625	10	0.4	19	0.7	743	28.6	6	0.2
		15-20	2081	6	0.3	19	0.9	451	22.0	6	0.3
Females	**All cases**		**11161**	**52**	**0.5**	**159**	**1.4**	**2750**	**24.9**	**22**	**0.2**
	Age at baseline	<18	2451	5	0.2	45	1.8	738	30.3	10	0.4
		18-19	951	5	0.5	18	1.9	251	26.7	.	.
		20-24	2645	16	0.6	40	1.5	698	26.6	6	0.2
		25-29	2330	12	0.5	27	1.2	559	24.2	3	0.1
		30-34	1677	7	0.4	16	1.0	334	20.2	2	0.1
		35+	1107	7	0.6	13	1.2	170	15.6	1	0.1
	Years since diagnosis	5-9	1060	.	.	20	1.9	319	30.4	3	0.3
		10-14	3597	18	0.5	48	1.3	964	27.0	9	0.3
		15-19	3648	17	0.5	56	1.5	877	24.3	9	0.2
		20+	2856	17	0.6	35	1.2	590	20.9	1	0.0
	Age at diagnosis	<1	882	.	.	18	2.1	127	14.5	5	0.6
		1-4	3679	16	0.4	61	1.7	1095	30.0	6	0.2
		5-9	2338	16	0.7	26	1.1	646	27.8	3	0.1
		10-14	2401	14	0.6	43	1.8	602	25.3	4	0.2
		15-20	1861	6	0.3	11	0.6	280	15.3	4	0.2

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - AntiMetabolites: All cancers

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**23716**	**40**	**0.2**	**5365**	**22.9**	**8846**	**37.8**	**2323**	**9.9**
	Age at baseline	<18	5295	12	0.2	1464	28.0	1923	36.8	586	11.2
		18-19	1964	5	0.3	569	29.4	782	40.4	216	11.1
		20-24	5511	12	0.2	1383	25.4	2106	38.6	533	9.8
		25-29	5150	7	0.1	1089	21.4	2034	40.0	523	10.3
		30-34	3566	3	0.1	582	16.6	1335	38.0	301	8.6
		35+	2230	1	0.0	278	12.7	666	30.3	164	7.5
	Years since diagnosis	5-9	2391	1	0.0	541	23.1	923	39.3	221	9.4
		10-14	7681	29	0.4	1886	24.8	3044	40.1	849	11.1
		15-19	7592	10	0.1	1739	23.2	2872	38.3	736	9.8
		20+	6052	.	.	1199	20.1	2007	33.6	517	8.6
	Age at diagnosis	<1	1789	6	0.3	117	6.6	189	10.6	110	6.2
		1-4	7646	12	0.2	2505	33.2	3167	42.0	881	11.6
		5-9	5313	9	0.2	1361	25.9	2144	40.9	521	9.9
		10-14	5026	9	0.2	939	18.9	2050	41.2	555	11.1
		15-20	3942	4	0.1	443	11.4	1296	33.5	256	6.6
Males	**All cases**		**12555**	**24**	**0.2**	**2804**	**22.6**	**4868**	**39.3**	**1295**	**10.4**
	Age at baseline	<18	2844	8	0.3	749	26.7	1025	36.6	322	11.4
		18-19	1013	4	0.4	285	28.4	428	42.7	127	12.6
		20-24	2866	7	0.2	693	24.4	1100	38.8	282	9.9
		25-29	2820	5	0.2	596	21.4	1170	42.1	307	11.0
		30-34	1889	.	.	310	16.6	755	40.5	161	8.6
		35+	1123	.	.	171	15.4	390	35.2	96	8.7
	Years since diagnosis	5-9	1331	1	0.1	284	21.8	519	39.8	130	9.9
		10-14	4084	19	0.5	992	24.6	1675	41.6	483	11.9
		15-19	3944	4	0.1	875	22.5	1543	39.6	381	9.8
		20+	3196	.	.	653	20.7	1131	35.8	301	9.5
	Age at diagnosis	<1	907	4	0.4	54	6.0	86	9.6	53	5.9
		1-4	3967	8	0.2	1258	32.1	1656	42.3	483	12.3
		5-9	2975	6	0.2	730	24.9	1222	41.7	316	10.8
		10-14	2625	4	0.2	487	18.8	1133	43.6	290	11.1
		15-20	2081	2	0.1	275	13.4	771	37.7	153	7.5
Females	**All cases**		**11161**	**16**	**0.1**	**2561**	**23.2**	**3978**	**36.1**	**1028**	**9.3**
	Age at baseline	<18	2451	4	0.2	715	29.4	898	37.0	264	10.8
		18-19	951	1	0.1	284	30.4	354	37.9	89	9.4
		20-24	2645	5	0.2	690	26.3	1006	38.4	251	9.6
		25-29	2330	2	0.1	493	21.4	864	37.5	216	9.3
		30-34	1677	3	0.2	272	16.5	580	35.1	140	8.5
		35+	1107	1	0.1	107	9.8	276	25.3	68	6.2
	Years since diagnosis	5-9	1060	.	.	257	24.7	404	38.7	91	8.7
		10-14	3597	10	0.3	894	25.1	1369	38.5	366	10.3
		15-19	3648	6	0.2	864	24.0	1329	36.9	355	9.8
		20+	2856	.	.	546	19.4	876	31.1	216	7.6
	Age at diagnosis	<1	882	2	0.2	63	7.2	103	11.7	57	6.5
		1-4	3679	4	0.1	1247	34.3	1511	41.6	398	10.9
		5-9	2338	3	0.1	631	27.2	922	39.8	205	8.8
		10-14	2401	5	0.2	452	19.0	917	38.6	265	11.1
		15-20	1861	2	0.1	168	9.2	525	28.7	103	5.6

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**7302**	**49**	**0.7**	**277**	**3.8**	**4794**	**66.5**	**2**	**0.0**
	Age at baseline	<18	2099	8	0.4	80	3.8	1433	69.0	1	0.0
		18-19	769	4	0.5	32	4.2	469	61.5	.	.
		20-24	1799	20	1.1	65	3.6	1166	65.4	.	.
		25-29	1471	13	0.9	46	3.1	952	65.3	1	0.1
		30-34	779	4	0.5	30	3.9	510	67.4	.	.
		35+	385	.	.	24	6.3	264	70.0	.	.
	Years since diagnosis	5-9	906	.	.	33	3.7	617	69.1	1	0.1
		10-14	2444	15	0.6	92	3.8	1718	71.0	.	.
		15-19	2246	21	0.9	87	3.9	1462	65.9	.	.
		20+	1706	13	0.8	65	3.8	997	59.3	1	0.1
	Age at diagnosis	<1	233	.	.	30	13.0	204	89.5	1	0.4
		1-4	3449	26	0.8	114	3.3	2117	61.9	1	0.0
		5-9	1767	17	1.0	42	2.4	1093	62.6	.	.
		10-14	1216	4	0.3	61	5.0	910	75.7	.	.
		15-20	637	2	0.3	30	4.8	470	75.9	.	.
Males	**All cases**		**3855**	**23**	**0.6**	**119**	**3.1**	**2565**	**67.5**	**1**	**0.0**
	Age at baseline	<18	1137	4	0.4	35	3.1	777	69.3	.	.
		18-19	410	1	0.2	15	3.7	253	62.0	.	.
		20-24	895	8	0.9	25	2.8	581	65.4	.	.
		25-29	788	8	1.0	19	2.4	518	66.7	1	0.1
		30-34	411	2	0.5	14	3.5	286	72.0	.	.
		35+	214	.	.	11	5.2	150	71.8	.	.
	Years since diagnosis	5-9	510	.	.	13	2.6	347	69.0	.	.
		10-14	1300	5	0.4	44	3.4	914	71.0	.	.
		15-19	1138	12	1.1	32	2.8	753	67.4	.	.
		20+	907	6	0.7	30	3.3	551	61.6	1	0.1
	Age at diagnosis	<1	111	.	.	13	11.9	95	88.8	.	.
		1-4	1822	12	0.7	53	2.9	1130	62.6	1	0.1
		5-9	942	8	0.9	16	1.7	603	65.1	.	.
		10-14	596	2	0.3	18	3.0	454	76.9	.	.
		15-20	384	1	0.3	19	5.1	283	76.1	.	.
Females	**All cases**		**3447**	**26**	**0.8**	**158**	**4.6**	**2229**	**65.3**	**1**	**0.0**
	Age at baseline	<18	962	4	0.4	45	4.7	656	68.6	1	0.1
		18-19	359	3	0.8	17	4.8	216	61.0	.	.
		20-24	904	12	1.3	40	4.5	585	65.4	.	.
		25-29	683	5	0.7	27	4.0	434	63.8	.	.
		30-34	368	2	0.5	16	4.4	224	62.2	.	.
		35+	171	.	.	13	7.7	114	67.9	.	.
	Years since diagnosis	5-9	396	.	.	20	5.1	270	69.2	1	0.3
		10-14	1144	10	0.9	48	4.2	804	70.9	.	.
		15-19	1108	9	0.8	55	5.0	709	64.4	.	.
		20+	799	7	0.9	35	4.4	446	56.6	.	.
	Age at diagnosis	<1	122	.	.	17	13.9	109	90.1	1	0.8
		1-4	1627	14	0.9	61	3.8	987	61.2	.	.
		5-9	825	9	1.1	26	3.2	490	59.8	.	.
		10-14	620	2	0.3	43	7.0	456	74.5	.	.
		15-20	253	1	0.4	11	4.4	187	75.7	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - AntiMetabolites: All leukemias

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**7302**	**35**	**0.5**	**4867**	**68.0**	**5816**	**81.3**	**1899**	**26.3**
	Age at baseline	<18	2099	12	0.6	1417	69.1	1650	80.5	518	25.0
		18-19	769	5	0.7	541	71.8	623	83.0	179	23.5
		20-24	1799	9	0.5	1272	71.7	1486	83.9	446	25.0
		25-29	1471	7	0.5	949	65.6	1171	80.9	410	28.1
		30-34	779	1	0.1	465	61.7	597	79.2	218	28.8
		35+	385	1	0.3	223	59.0	289	76.5	128	33.7
	Years since diagnosis	5-9	906	1	0.1	506	57.6	637	72.4	193	21.7
		10-14	2444	28	1.2	1729	72.0	2039	85.2	688	28.5
		15-19	2246	6	0.3	1564	70.9	1832	83.0	598	26.9
		20+	1706	.	.	1068	63.8	1308	78.1	420	24.9
	Age at diagnosis	<1	233	6	2.6	112	48.9	165	72.1	99	42.9
		1-4	3449	10	0.3	2438	72.0	2788	82.4	784	23.0
		5-9	1767	9	0.5	1201	69.6	1409	81.7	402	23.1
		10-14	1216	6	0.5	770	64.2	970	80.9	420	34.9
		15-20	637	4	0.6	346	56.0	484	78.2	194	31.2
Males	**All cases**		**3855**	**21**	**0.5**	**2486**	**65.9**	**3015**	**79.9**	**1026**	**27.0**
	Age at baseline	<18	1137	8	0.7	717	64.9	842	76.3	279	25.0
		18-19	410	4	1.0	269	66.3	320	79.2	99	24.3
		20-24	895	4	0.4	624	70.4	735	83.0	231	26.1
		25-29	788	5	0.6	505	65.5	628	81.3	232	29.8
		30-34	411	.	.	235	59.3	323	81.4	111	28.0
		35+	214	.	.	136	64.5	167	79.1	74	35.1
	Years since diagnosis	5-9	510	1	0.2	257	51.9	339	68.5	108	21.6
		10-14	1300	18	1.4	889	69.8	1056	83.2	377	29.5
		15-19	1138	2	0.2	773	69.2	922	82.5	301	26.9
		20+	907	.	.	567	63.7	698	78.3	240	26.8
	Age at diagnosis	<1	111	4	3.7	53	49.1	79	73.1	46	42.2
		1-4	1822	6	0.3	1221	68.2	1410	78.8	424	23.5
		5-9	942	6	0.6	625	68.2	736	80.4	238	25.8
		10-14	596	3	0.5	374	63.8	493	84.0	202	34.3
		15-20	384	2	0.5	213	57.0	297	79.4	116	31.1
Females	**All cases**		**3447**	**14**	**0.4**	**2381**	**70.4**	**2801**	**82.9**	**873**	**25.6**
	Age at baseline	<18	962	4	0.4	700	74.0	808	85.4	239	25.1
		18-19	359	1	0.3	272	78.4	303	87.3	80	22.5
		20-24	904	5	0.6	648	73.0	751	84.8	215	24.0
		25-29	683	2	0.3	444	65.7	543	80.3	178	26.1
		30-34	368	1	0.3	230	64.2	274	76.8	107	29.6
		35+	171	1	0.6	87	52.1	122	73.1	54	32.0
	Years since diagnosis	5-9	396	.	.	249	65.0	298	77.4	85	21.9
		10-14	1144	10	0.9	840	74.5	983	87.5	311	27.5
		15-19	1108	4	0.4	791	72.7	910	83.6	297	26.9
		20+	799	.	.	501	63.9	610	78.0	180	22.8
	Age at diagnosis	<1	122	2	1.6	59	48.8	86	71.1	53	43.4
		1-4	1627	4	0.2	1217	76.4	1378	86.6	360	22.3
		5-9	825	3	0.4	576	71.1	673	83.2	164	20.0
		10-14	620	3	0.5	396	64.5	477	77.9	218	35.4
		15-20	253	2	0.8	133	54.5	187	76.3	78	31.5

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

Chemotherapy agents - AntiMetabolites: ALL

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**6109**	**43**	**0.7**	**9**	**0.1**	**3791**	**62.7**	**1**	**0.0**
	Age at baseline	<18	1814	8	0.4	5	0.3	1183	65.8	.	.
		18-19	666	4	0.6	1	0.2	382	57.9	.	.
		20-24	1532	16	1.1	1	0.1	934	61.4	.	.
		25-29	1217	13	1.1	1	0.1	738	61.1	1	0.1
		30-34	604	2	0.3	1	0.2	371	63.2	.	.
		35+	276	.	.	.	.	183	67.3	.	.
	Years since diagnosis	5-9	778	.	.	1	0.1	521	67.8	.	.
		10-14	2048	12	0.6	4	0.2	1378	67.9	.	.
		15-19	1853	18	1.0	2	0.1	1116	60.9	.	.
		20+	1430	13	0.9	2	0.1	776	54.9	1	0.1
	Age at diagnosis	<1	128	.	.	.	.	110	87.3	.	.
		1-4	3055	26	0.9	7	0.2	1770	58.4	1	0.0
		5-9	1545	15	1.0	1	0.1	906	59.4	.	.
		10-14	949	2	0.2	1	0.1	687	72.9	.	.
		15-20	432	.	.	.	.	318	75.9	.	.
Males	**All cases**		**3252**	**21**	**0.7**	**2**	**0.1**	**2065**	**64.2**	**1**	**0.0**
	Age at baseline	<18	982	4	0.4	.	.	644	66.3	.	.
		18-19	358	1	0.3	1	0.3	207	58.1	.	.
		20-24	762	7	0.9	.	.	465	61.4	.	.
		25-29	665	8	1.2	.	.	421	63.9	1	0.2
		30-34	324	1	0.3	1	0.3	217	69.3	.	.
		35+	161	.	.	.	.	111	69.8	.	.
	Years since diagnosis	5-9	439	.	.	.	.	291	67.2	.	.
		10-14	1098	5	0.5	1	0.1	743	68.2	.	.
		15-19	950	10	1.1	.	.	593	63.3	.	.
		20+	765	6	0.8	1	0.1	438	57.9	1	0.1
	Age at diagnosis	<1	64	.	.	.	.	56	88.9	.	.
		1-4	1603	12	0.8	1	0.1	938	58.9	1	0.1
		5-9	833	7	0.8	1	0.1	512	62.4	.	.
		10-14	483	2	0.4	.	.	360	74.8	.	.
		15-20	269	.	.	.	.	199	76.5	.	.
Females	**All cases**		**2857**	**22**	**0.8**	**7**	**0.2**	**1726**	**61.0**	**.**	**.**
	Age at baseline	<18	832	4	0.5	5	0.6	539	65.3	.	.
		18-19	308	3	1.0	.	.	175	57.6	.	.
		20-24	770	9	1.2	1	0.1	469	61.5	.	.
		25-29	552	5	0.9	1	0.2	317	57.7	.	.
		30-34	280	1	0.4	.	.	154	56.2	.	.
		35+	115	.	.	.	.	72	63.7	.	.
	Years since diagnosis	5-9	339	.	.	1	0.3	230	68.7	.	.
		10-14	950	7	0.7	3	0.3	635	67.5	.	.
		15-19	903	8	0.9	2	0.2	523	58.3	.	.
		20+	665	7	1.1	1	0.2	338	51.5	.	.
	Age at diagnosis	<1	64	.	.	.	.	54	85.7	.	.
		1-4	1452	14	1.0	6	0.4	832	57.8	.	.
		5-9	712	8	1.1	.	.	394	55.8	.	.
		10-14	466	.	.	1	0.2	327	70.9	.	.
		15-20	163	.	.	.	.	119	74.8	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**6109**	**3**	**0.0**	**4701**	**78.6**	**5258**	**88.0**	**1214**	**20.1**
	Age at baseline	<18	1814	.	.	1381	78.0	1524	86.2	333	18.6
		18-19	666	1	0.2	528	81.1	577	88.9	120	18.2
		20-24	1532	1	0.1	1230	81.6	1351	89.6	283	18.6
		25-29	1217	1	0.1	911	76.1	1048	87.4	260	21.5
		30-34	604	.	.	443	75.9	514	88.2	131	22.2
		35+	276	.	.	208	77.0	244	90.4	87	31.9
	Years since diagnosis	5-9	778	1	0.1	492	65.4	576	76.4	139	18.2
		10-14	2048	1	0.0	1680	83.6	1852	92.4	450	22.2
		15-19	1853	1	0.1	1507	82.9	1644	90.5	349	19.0
		20+	1430	.	.	1022	72.8	1186	84.6	276	19.5
	Age at diagnosis	<1	128	.	.	97	77.0	116	92.1	26	20.5
		1-4	3055	1	0.0	2377	79.4	2605	87.1	538	17.8
		5-9	1545	1	0.1	1168	77.5	1307	86.7	265	17.4
		10-14	949	.	.	740	78.7	848	90.2	267	28.3
		15-20	432	1	0.2	319	77.1	382	92.0	118	28.1
Males	**All cases**		**3252**	**3**	**0.1**	**2408**	**75.6**	**2745**	**86.2**	**686**	**21.4**
	Age at baseline	<18	982	.	.	703	73.7	780	81.9	181	18.7
		18-19	358	1	0.3	264	74.6	298	84.7	66	18.6
		20-24	762	1	0.1	600	79.7	667	88.5	149	19.7
		25-29	665	1	0.2	489	75.0	573	87.6	163	24.7
		30-34	324	.	.	226	72.4	280	89.7	70	22.4
		35+	161	.	.	126	79.2	147	92.5	57	35.6
	Years since diagnosis	5-9	439	1	0.2	251	59.1	301	70.8	81	18.8
		10-14	1098	1	0.1	866	80.6	968	90.3	255	23.5
		15-19	950	1	0.1	748	80.2	834	89.4	180	19.2
		20+	765	.	.	543	72.2	642	85.3	170	22.4
	Age at diagnosis	<1	64	.	.	47	74.6	58	92.1	13	20.6
		1-4	1603	1	0.1	1193	75.8	1318	83.8	284	17.9
		5-9	833	1	0.1	610	75.3	692	85.5	173	21.1
		10-14	483	.	.	362	75.7	440	91.7	144	29.9
		15-20	269	1	0.4	196	75.7	237	91.5	72	27.6
Females	**All cases**		**2857**	**.**	**.**	**2293**	**82.0**	**2513**	**89.9**	**528**	**18.7**
	Age at baseline	<18	832	.	.	678	83.0	744	91.1	152	18.4
		18-19	308	.	.	264	88.9	279	93.9	54	17.7
		20-24	770	.	.	630	83.4	684	90.7	134	17.6
		25-29	552	.	.	422	77.4	475	87.2	97	17.6
		30-34	280	.	.	217	79.8	234	86.3	61	22.1
		35+	115	.	.	82	73.9	97	87.4	30	26.5
	Years since diagnosis	5-9	339	.	.	241	73.7	275	83.6	58	17.4
		10-14	950	.	.	814	87.1	884	94.7	195	20.7
		15-19	903	.	.	759	85.9	810	91.6	169	18.8
		20+	665	.	.	479	73.6	544	83.8	106	16.1
	Age at diagnosis	<1	64	.	.	50	79.4	58	92.1	13	20.3
		1-4	1452	.	.	1184	83.4	1287	90.8	254	17.7
		5-9	712	.	.	558	79.9	615	88.1	92	13.0
		10-14	466	.	.	378	81.8	408	88.7	123	26.6
		15-20	163	.	.	123	79.4	145	92.9	46	28.9

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**882**	**5**	**0.6**	**250**	**28.8**	**824**	**95.0**	**1**	**0.1**
	Age at baseline	<18	225	.	.	70	31.8	211	95.5	1	0.4
		18-19	82	.	.	29	35.8	74	91.4	.	.
		20-24	193	4	2.1	63	33.3	184	96.3	.	.
		25-29	188	.	.	41	21.9	181	97.3	.	.
		30-34	121	1	0.8	25	21.0	109	92.4	.	.
		35+	73	.	.	22	30.6	65	92.9	.	.
	Years since diagnosis	5-9	81	.	.	32	41.0	76	96.2	1	1.3
		10-14	307	2	0.7	83	27.4	289	95.1	.	.
		15-19	304	3	1.0	78	25.9	285	95.3	.	.
		20+	190	.	.	57	30.6	174	94.1	.	.
	Age at diagnosis	<1	90	.	.	27	30.3	84	94.4	1	1.1
		1-4	301	.	.	102	34.5	283	95.6	.	.
		5-9	166	2	1.2	38	23.3	156	95.1	.	.
		10-14	186	2	1.1	55	30.2	175	96.2	.	.
		15-20	139	1	0.7	28	20.3	126	92.6	.	.
Males	**All cases**		**430**	**2**	**0.5**	**108**	**25.7**	**398**	**95.0**	**.**	**.**
	Age at baseline	<18	122	.	.	32	27.1	112	94.9	.	.
		18-19	42	.	.	13	31.0	39	92.9	.	.
		20-24	92	1	1.1	25	27.8	88	96.7	.	.
		25-29	82	.	.	16	19.8	78	97.5	.	.
		30-34	58	1	1.8	12	21.1	52	92.9	.	.
		35+	34	.	.	10	30.3	29	90.6	.	.
	Years since diagnosis	5-9	47	.	.	13	28.9	44	95.7	.	.
		10-14	152	.	.	41	27.3	145	97.3	.	.
		15-19	141	2	1.4	28	20.1	128	93.4	.	.
		20+	90	.	.	26	29.9	81	93.1	.	.
	Age at diagnosis	<1	39	.	.	12	31.6	35	92.1	.	.
		1-4	165	.	.	48	29.6	154	95.7	.	.
		5-9	76	1	1.4	14	18.9	71	95.9	.	.
		10-14	75	.	.	17	23.3	69	94.5	.	.
		15-20	75	1	1.4	17	23.0	69	94.5	.	.
Females	**All cases**		**452**	**3**	**0.7**	**142**	**31.8**	**426**	**95.1**	**1**	**0.2**
	Age at baseline	<18	103	.	.	38	37.3	99	96.1	1	1.0
		18-19	40	.	.	16	41.0	35	89.7	.	.
		20-24	101	3	3.0	38	38.4	96	96.0	.	.
		25-29	106	.	.	25	23.6	103	97.2	.	.
		30-34	63	.	.	13	21.0	57	91.9	.	.
		35+	39	.	.	12	30.8	36	94.7	.	.
	Years since diagnosis	5-9	34	.	.	19	57.6	32	97.0	1	3.0
		10-14	155	2	1.3	42	27.5	144	92.9	.	.
		15-19	163	1	0.6	50	30.9	157	96.9	.	.
		20+	100	.	.	31	31.3	93	94.9	.	.
	Age at diagnosis	<1	51	.	.	15	29.4	49	96.1	1	2.0
		1-4	136	.	.	54	40.3	129	95.6	.	.
		5-9	90	1	1.1	24	27.0	85	94.4	.	.
		10-14	111	2	1.8	38	34.9	106	97.2	.	.
		15-20	64	.	.	11	17.2	57	90.5	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**882**	**31**	**3.5**	**91**	**10.4**	**392**	**45.0**	**597**	**69.3**
	Age at baseline	<18	225	11	4.9	21	9.5	94	42.3	168	77.1
		18-19	82	4	4.9	6	7.4	37	45.7	51	63.0
		20-24	193	8	4.2	17	8.9	91	47.6	134	71.3
		25-29	188	6	3.2	27	14.4	88	47.1	135	72.6
		30-34	121	1	0.8	12	10.2	54	45.4	73	62.4
		35+	73	1	1.4	8	11.1	28	38.9	36	50.7
	Years since diagnosis	5-9	81	.	.	6	7.6	40	50.6	50	64.1
		10-14	307	26	8.5	27	8.9	139	45.9	216	71.8
		15-19	304	5	1.7	37	12.3	142	46.9	208	69.8
		20+	190	.	.	21	11.3	71	38.0	123	66.8
	Age at diagnosis	<1	90	5	5.6	13	14.6	39	43.8	67	75.3
		1-4	301	9	3.0	27	9.0	127	42.3	213	72.7
		5-9	166	8	4.8	17	10.4	73	44.8	115	71.4
		10-14	186	6	3.3	17	9.4	85	47.0	134	73.6
		15-20	139	3	2.2	17	12.2	68	48.9	68	50.0
Males	**All cases**		**430**	**18**	**4.2**	**35**	**8.3**	**173**	**40.7**	**283**	**68.4**
	Age at baseline	<18	122	8	6.6	7	5.9	45	37.5	89	76.1
		18-19	42	3	7.1	2	4.8	18	42.9	27	64.3
		20-24	92	3	3.3	8	8.7	41	44.6	63	71.6
		25-29	82	4	4.9	9	11.1	34	42.0	59	73.8
		30-34	58	.	.	5	8.9	25	43.9	32	58.2
		35+	34	.	.	4	12.1	10	30.3	13	40.6
	Years since diagnosis	5-9	47	.	.	3	6.5	25	54.3	24	53.3
		10-14	152	17	11.3	10	6.7	60	40.0	110	74.3
		15-19	141	1	0.7	15	10.7	63	44.7	94	69.1
		20+	90	.	.	7	8.0	25	28.4	55	64.7
	Age at diagnosis	<1	39	4	10.5	6	15.8	16	42.1	31	81.6
		1-4	165	5	3.0	8	4.9	61	37.0	117	73.1
		5-9	76	5	6.7	7	9.5	28	37.3	50	70.4
		10-14	75	3	4.1	4	5.6	32	44.4	49	67.1
		15-20	75	1	1.3	10	13.3	36	48.0	36	50.0
Females	**All cases**		**452**	**13**	**2.9**	**56**	**12.5**	**219**	**49.0**	**314**	**70.2**
	Age at baseline	<18	103	3	2.9	14	13.7	49	48.0	79	78.2
		18-19	40	1	2.6	4	10.3	19	48.7	24	61.5
		20-24	101	5	5.0	9	9.0	50	50.5	71	71.0
		25-29	106	2	1.9	18	17.0	54	50.9	76	71.7
		30-34	63	1	1.6	7	11.3	29	46.8	41	66.1
		35+	39	1	2.6	4	10.3	18	46.2	23	59.0
	Years since diagnosis	5-9	34	.	.	3	9.1	15	45.5	26	78.8
		10-14	155	9	5.8	17	11.0	79	51.6	106	69.3
		15-19	163	4	2.5	22	13.6	79	48.8	114	70.4
		20+	100	.	.	14	14.1	46	46.5	68	68.7
	Age at diagnosis	<1	51	1	2.0	7	13.7	23	45.1	36	70.6
		1-4	136	4	3.0	19	14.1	66	48.9	96	72.2
		5-9	90	3	3.3	10	11.2	45	51.1	65	72.2
		10-14	111	3	2.8	13	11.9	53	48.6	85	78.0
		15-20	64	2	3.1	7	10.9	32	50.0	32	50.0

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**4211**	**2**	**0.0**	**1**	**0.0**	**157**	**3.8**	**11**	**0.3**
	Age at baseline	<18	891	1	0.1	.	.	53	6.0	3	0.3
		18-19	349	.	.	1	0.3	9	2.7	1	0.3
		20-24	1103	1	0.1	.	.	32	2.9	3	0.3
		25-29	1029	.	.	.	.	36	3.5	3	0.3
		30-34	586	.	.	.	.	19	3.3	1	0.2
		35+	253	.	.	.	.	8	3.2	.	.
	Years since diagnosis	5-9	430	.	.	.	.	46	10.9	.	.
		10-14	1427	2	0.1	.	.	37	2.6	7	0.5
		15-19	1335	.	.	1	0.1	13	1.0	4	0.3
		20+	1019	.	.	.	.	61	6.0	.	.
	Age at diagnosis	<1	206	.	.	1	0.5	11	5.4	2	1.0
		1-4	1231	.	.	.	.	53	4.4	2	0.2
		5-9	1331	2	0.2	.	.	54	4.1	2	0.2
		10-14	1005	.	.	.	.	30	3.0	4	0.4
		15-20	438	.	.	.	.	9	2.1	1	0.2
Males	**All cases**		**2292**	**1**	**0.0**	**.**	**.**	**91**	**4.0**	**8**	**0.4**
	Age at baseline	<18	494	.	.	.	.	34	7.0	2	0.4
		18-19	177	.	.	.	.	4	2.3	1	0.6
		20-24	590	1	0.2	.	.	18	3.1	2	0.3
		25-29	584	.	.	.	.	24	4.2	3	0.5
		30-34	312	.	.	.	.	9	2.9	.	.
		35+	135	.	.	.	.	2	1.6	.	.
	Years since diagnosis	5-9	244	.	.	.	.	28	11.8	.	.
		10-14	768	1	0.1	.	.	25	3.3	5	0.7
		15-19	726	.	.	.	.	7	1.0	3	0.4
		20+	554	.	.	.	.	31	5.7	.	.
	Age at diagnosis	<1	121	.	.	.	.	7	5.8	2	1.7
		1-4	652	.	.	.	.	30	4.7	1	0.2
		5-9	741	1	0.1	.	.	31	4.2	1	0.1
		10-14	531	.	.	.	.	16	3.1	4	0.8
		15-20	247	.	.	.	.	7	2.9	.	.
Females	**All cases**		**1919**	**1**	**0.1**	**1**	**0.1**	**66**	**3.5**	**3**	**0.2**
	Age at baseline	<18	397	1	0.3	.	.	19	4.8	1	0.3
		18-19	172	.	.	1	0.6	5	3.0	.	.
		20-24	513	.	.	.	.	14	2.8	1	0.2
		25-29	445	.	.	.	.	12	2.7	.	.
		30-34	274	.	.	.	.	10	3.7	1	0.4
		35+	118	.	.	.	.	6	5.1	.	.
	Years since diagnosis	5-9	186	.	.	.	.	18	9.8	.	.
		10-14	659	1	0.2	.	.	12	1.8	2	0.3
		15-19	609	.	.	1	0.2	6	1.0	1	0.2
		20+	465	.	.	.	.	30	6.5	.	.
	Age at diagnosis	<1	85	.	.	1	1.2	4	4.7	.	.
		1-4	579	.	.	.	.	23	4.0	1	0.2
		5-9	590	1	0.2	.	.	23	3.9	1	0.2
		10-14	474	.	.	.	.	14	3.0	.	.
		15-20	191	.	.	.	.	2	1.1	1	0.5

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**4211**	**.**	**.**	**7**	**0.2**	**59**	**1.4**	**68**	**1.6**
	Age at baseline	<18	891	.	.	1	0.1	18	2.0	25	2.8
		18-19	349	.	.	.	.	6	1.8	8	2.3
		20-24	1103	.	.	2	0.2	19	1.7	15	1.4
		25-29	1029	.	.	3	0.3	9	0.9	15	1.5
		30-34	586	.	.	.	.	7	1.2	3	0.5
		35+	253	.	.	1	0.4	.	.	2	0.8
	Years since diagnosis	5-9	430	.	.	1	0.2	12	2.8	6	1.4
		10-14	1427	.	.	1	0.1	17	1.2	38	2.7
		15-19	1335	.	.	2	0.2	16	1.2	18	1.4
		20+	1019	.	.	3	0.3	14	1.4	6	0.6
	Age at diagnosis	<1	206	.	.	.	.	9	4.4	8	3.9
		1-4	1231	.	.	3	0.2	18	1.5	26	2.1
		5-9	1331	.	.	4	0.3	18	1.4	15	1.1
		10-14	1005	.	.	.	.	11	1.1	13	1.3
		15-20	438	.	.	.	.	3	0.7	6	1.4
Males	**All cases**		**2292**	**.**	**.**	**5**	**0.2**	**38**	**1.7**	**39**	**1.7**
	Age at baseline	<18	494	.	.	1	0.2	10	2.1	17	3.5
		18-19	177	.	.	.	.	3	1.7	4	2.3
		20-24	590	.	.	2	0.3	13	2.2	8	1.4
		25-29	584	.	.	2	0.3	8	1.4	7	1.2
		30-34	312	.	.	.	.	4	1.3	1	0.3
		35+	135	.	.	.	.	.	.	2	1.6
	Years since diagnosis	5-9	244	.	.	1	0.4	8	3.3	4	1.7
		10-14	768	.	.	1	0.1	10	1.3	24	3.2
		15-19	726	.	.	2	0.3	10	1.4	8	1.1
		20+	554	.	.	1	0.2	10	1.8	3	0.5
	Age at diagnosis	<1	121	.	.	.	.	4	3.3	7	5.8
		1-4	652	.	.	2	0.3	12	1.9	13	2.0
		5-9	741	.	.	3	0.4	13	1.8	9	1.2
		10-14	531	.	.	.	.	7	1.3	5	1.0
		15-20	247	.	.	.	.	2	0.8	5	2.1
Females	**All cases**		**1919**	**.**	**.**	**2**	**0.1**	**21**	**1.1**	**29**	**1.5**
	Age at baseline	<18	397	.	.	.	.	8	2.0	8	2.0
		18-19	172	.	.	.	.	3	1.8	4	2.4
		20-24	513	.	.	.	.	6	1.2	7	1.4
		25-29	445	.	.	1	0.2	1	0.2	8	1.8
		30-34	274	.	.	.	.	3	1.1	2	0.7
		35+	118	.	.	1	0.8	.	.	.	.
	Years since diagnosis	5-9	186	.	.	.	.	4	2.2	2	1.1
		10-14	659	.	.	.	.	7	1.1	14	2.1
		15-19	609	.	.	.	.	6	1.0	10	1.7
		20+	465	.	.	2	0.4	4	0.9	3	0.6
	Age at diagnosis	<1	85	.	.	.	.	5	5.9	1	1.2
		1-4	579	.	.	1	0.2	6	1.1	13	2.3
		5-9	590	.	.	1	0.2	5	0.9	6	1.0
		10-14	474	.	.	.	.	4	0.8	8	1.7
		15-20	191	.	.	.	.	1	0.5	1	0.5

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2528**	**.**	**.**	**.**	**.**	**52**	**2.1**	**10**	**0.4**
	Age at baseline	<18	493	.	.	.	.	17	3.5	2	0.4
		18-19	202	.	.	.	.	1	0.5	1	0.5
		20-24	668	.	.	.	.	11	1.7	3	0.5
		25-29	636	.	.	.	.	14	2.2	3	0.5
		30-34	360	.	.	.	.	8	2.2	1	0.3
		35+	169	.	.	.	.	1	0.6	.	.
	Years since diagnosis	5-9	220	.	.	.	.	12	5.5	.	.
		10-14	840	.	.	.	.	16	1.9	6	0.7
		15-19	784	.	.	.	.	2	0.3	4	0.5
		20+	684	.	.	.	.	22	3.2	.	.
	Age at diagnosis	<1	145	.	.	.	.	7	4.8	2	1.4
		1-4	748	.	.	.	.	11	1.5	1	0.1
		5-9	753	.	.	.	.	21	2.8	2	0.3
		10-14	603	.	.	.	.	10	1.7	4	0.7
		15-20	279	.	.	.	.	3	1.1	1	0.4
Males	**All cases**		**1315**	**.**	**.**	**.**	**.**	**35**	**2.7**	**8**	**0.6**
	Age at baseline	<18	258	.	.	.	.	16	6.3	2	0.8
		18-19	102	.	.	.	.	1	1.0	1	1.0
		20-24	329	.	.	.	.	7	2.1	2	0.6
		25-29	356	.	.	.	.	7	2.0	3	0.8
		30-34	181	.	.	.	.	4	2.2	.	.
		35+	89	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	118	.	.	.	.	10	8.5	.	.
		10-14	438	.	.	.	.	14	3.2	5	1.2
		15-19	396	.	.	.	.	1	0.3	3	0.8
		20+	363	.	.	.	.	10	2.8	.	.
	Age at diagnosis	<1	81	.	.	.	.	6	7.4	2	2.5
		1-4	378	.	.	.	.	8	2.1	1	0.3
		5-9	397	.	.	.	.	14	3.6	1	0.3
		10-14	304	.	.	.	.	5	1.7	4	1.3
		15-20	155	.	.	.	.	2	1.3	.	.
Females	**All cases**		**1213**	**.**	**.**	**.**	**.**	**17**	**1.4**	**2**	**0.2**
	Age at baseline	<18	235	.	.	.	.	1	0.4	.	.
		18-19	100	.	.	.	.	.	.	.	.
		20-24	339	.	.	.	.	4	1.2	1	0.3
		25-29	280	.	.	.	.	7	2.5	.	.
		30-34	179	.	.	.	.	4	2.2	1	0.6
		35+	80	.	.	.	.	1	1.3	.	.
	Years since diagnosis	5-9	102	.	.	.	.	2	2.0	.	.
		10-14	402	.	.	.	.	2	0.5	1	0.3
		15-19	388	.	.	.	.	1	0.3	1	0.3
		20+	321	.	.	.	.	12	3.8	.	.
	Age at diagnosis	<1	64	.	.	.	.	1	1.6	.	.
		1-4	370	.	.	.	.	3	0.8	.	.
		5-9	356	.	.	.	.	7	2.0	1	0.3
		10-14	299	.	.	.	.	5	1.7	.	.
		15-20	124	.	.	.	.	1	0.8	1	0.8

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2528**	**.**	**.**	**1**	**0.0**	**18**	**0.7**	**56**	**2.2**
	Age at baseline	<18	493	.	.	.	.	4	0.8	20	4.1
		18-19	202	.	.	.	.	3	1.5	6	3.0
		20-24	668	.	.	1	0.2	6	0.9	13	2.0
		25-29	636	.	.	.	.	2	0.3	14	2.2
		30-34	360	.	.	.	.	3	0.8	1	0.3
		35+	169	.	.	.	.	.	.	2	1.2
	Years since diagnosis	5-9	220	.	.	.	.	.	.	5	2.3
		10-14	840	.	.	1	0.1	5	0.6	33	4.0
		15-19	784	.	.	.	.	7	0.9	13	1.7
		20+	684	.	.	.	.	6	0.9	5	0.7
	Age at diagnosis	<1	145	.	.	.	.	5	3.4	6	4.1
		1-4	748	.	.	.	.	5	0.7	20	2.7
		5-9	753	.	.	1	0.1	5	0.7	14	1.9
		10-14	603	.	.	.	.	3	0.5	10	1.7
		15-20	279	.	.	.	.	.	.	6	2.2
Males	**All cases**		**1315**	**.**	**.**	**1**	**0.1**	**11**	**0.8**	**33**	**2.5**
	Age at baseline	<18	258	.	.	.	.	3	1.2	14	5.5
		18-19	102	.	.	.	.	.	.	3	3.0
		20-24	329	.	.	1	0.3	5	1.5	6	1.8
		25-29	356	.	.	.	.	2	0.6	7	2.0
		30-34	181	.	.	.	.	1	0.6	1	0.6
		35+	89	.	.	.	.	.	.	2	2.3
	Years since diagnosis	5-9	118	.	.	.	.	.	.	3	2.5
		10-14	438	.	.	1	0.2	5	1.2	21	4.8
		15-19	396	.	.	.	.	2	0.5	7	1.8
		20+	363	.	.	.	.	4	1.1	2	0.6
	Age at diagnosis	<1	81	.	.	.	.	2	2.5	5	6.2
		1-4	378	.	.	.	.	3	0.8	10	2.7
		5-9	397	.	.	1	0.3	5	1.3	9	2.3
		10-14	304	.	.	.	.	1	0.3	4	1.3
		15-20	155	.	.	.	.	.	.	5	3.3
Females	**All cases**		**1213**	**.**	**.**	**.**	**.**	**7**	**0.6**	**23**	**1.9**
	Age at baseline	<18	235	.	.	.	.	1	0.4	6	2.6
		18-19	100	.	.	.	.	3	3.1	3	3.1
		20-24	339	.	.	.	.	1	0.3	7	2.1
		25-29	280	.	.	.	.	.	.	7	2.5
		30-34	179	.	.	.	.	2	1.1	.	.
		35+	80	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	102	.	.	.	.	.	.	2	2.0
		10-14	402	.	.	.	.	.	.	12	3.0
		15-19	388	.	.	.	.	5	1.3	6	1.6
		20+	321	.	.	.	.	2	0.6	3	0.9
	Age at diagnosis	<1	64	.	.	.	.	3	4.7	1	1.6
		1-4	370	.	.	.	.	2	0.5	10	2.7
		5-9	356	.	.	.	.	.	.	5	1.4
		10-14	299	.	.	.	.	2	0.7	6	2.0
		15-20	124	.	.	.	.	.	.	1	0.8

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**983**	**2**	**0.2**	**.**	**.**	**80**	**8.3**	**.**	**.**
	Age at baseline	<18	233	1	0.4	.	.	26	11.3	.	.
		18-19	77	.	.	.	.	5	6.8	.	.
		20-24	276	1	0.4	.	.	14	5.1	.	.
		25-29	236	.	.	.	.	17	7.3	.	.
		30-34	127	.	.	.	.	11	8.7	.	.
		35+	34	.	.	.	.	7	21.9	.	.
	Years since diagnosis	5-9	120	.	.	.	.	22	19.1	.	.
		10-14	334	2	0.6	.	.	17	5.2	.	.
		15-19	325	.	.	.	.	9	2.8	.	.
		20+	204	.	.	.	.	32	15.9	.	.
	Age at diagnosis	<1	23	.	.	.	.	1	4.5	.	.
		1-4	280	.	.	.	.	30	10.9	.	.
		5-9	402	2	0.5	.	.	28	7.0	.	.
		10-14	220	.	.	.	.	17	7.9	.	.
		15-20	58	.	.	.	.	4	7.3	.	.
Males	**All cases**		**600**	**1**	**0.2**	**.**	**.**	**46**	**7.8**	**.**	**.**
	Age at baseline	<18	141	.	.	.	.	15	10.9	.	.
		18-19	44	.	.	.	.	1	2.4	.	.
		20-24	178	1	0.6	.	.	8	4.6	.	.
		25-29	145	.	.	.	.	15	10.4	.	.
		30-34	71	.	.	.	.	5	7.1	.	.
		35+	21	.	.	.	.	2	10.5	.	.
	Years since diagnosis	5-9	73	.	.	.	.	12	17.6	.	.
		10-14	197	1	0.5	.	.	10	5.2	.	.
		15-19	207	.	.	.	.	5	2.4	.	.
		20+	123	.	.	.	.	19	15.8	.	.
	Age at diagnosis	<1	16	.	.	.	.	1	6.7	.	.
		1-4	168	.	.	.	.	17	10.3	.	.
		5-9	256	1	0.4	.	.	16	6.3	.	.
		10-14	125	.	.	.	.	9	7.4	.	.
		15-20	35	.	.	.	.	3	9.4	.	.
Females	**All cases**		**383**	**1**	**0.3**	**.**	**.**	**34**	**8.9**	**.**	**.**
	Age at baseline	<18	92	1	1.1	.	.	11	12.0	.	.
		18-19	33	.	.	.	.	4	12.5	.	.
		20-24	98	.	.	.	.	6	6.2	.	.
		25-29	91	.	.	.	.	2	2.2	.	.
		30-34	56	.	.	.	.	6	10.7	.	.
		35+	13	.	.	.	.	5	38.5	.	.
	Years since diagnosis	5-9	47	.	.	.	.	10	21.3	.	.
		10-14	137	1	0.7	.	.	7	5.1	.	.
		15-19	118	.	.	.	.	4	3.4	.	.
		20+	81	.	.	.	.	13	16.0	.	.
	Age at diagnosis	<1	7	.	.	.	.	.	.	.	.
		1-4	112	.	.	.	.	13	11.7	.	.
		5-9	146	1	0.7	.	.	12	8.3	.	.
		10-14	95	.	.	.	.	8	8.5	.	.
		15-20	23	.	.	.	.	1	4.3	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**983**	**.**	**.**	**5**	**0.5**	**31**	**3.2**	**6**	**0.6**
	Age at baseline	<18	233	.	.	1	0.4	9	3.9	3	1.3
		18-19	77	.	.	.	.	2	2.7	.	.
		20-24	276	.	.	1	0.4	11	4.0	1	0.4
		25-29	236	.	.	2	0.9	6	2.6	.	.
		30-34	127	.	.	.	.	3	2.4	2	1.6
		35+	34	.	.	1	3.1	.	.	.	.
	Years since diagnosis	5-9	120	.	.	1	0.9	8	6.9	1	0.9
		10-14	334	.	.	.	.	8	2.4	2	0.6
		15-19	325	.	.	2	0.6	8	2.5	2	0.6
		20+	204	.	.	2	1.0	7	3.5	1	0.5
	Age at diagnosis	<1	23	.	.	.	.	3	13.6	1	4.5
		1-4	280	.	.	2	0.7	9	3.3	3	1.1
		5-9	402	.	.	3	0.8	11	2.8	.	.
		10-14	220	.	.	.	.	6	2.8	2	0.9
		15-20	58	.	.	.	.	2	3.6	.	.
Males	**All cases**		**600**	**.**	**.**	**4**	**0.7**	**21**	**3.6**	**3**	**0.5**
	Age at baseline	<18	141	.	.	1	0.7	5	3.6	2	1.4
		18-19	44	.	.	.	.	2	4.8	.	.
		20-24	178	.	.	1	0.6	7	4.0	1	0.6
		25-29	145	.	.	2	1.4	5	3.5	.	.
		30-34	71	.	.	.	.	2	2.9	.	.
		35+	21	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	73	.	.	1	1.5	5	7.2	1	1.4
		10-14	197	.	.	.	.	4	2.1	1	0.5
		15-19	207	.	.	2	1.0	7	3.4	.	.
		20+	123	.	.	1	0.8	5	4.2	1	0.8
	Age at diagnosis	<1	16	.	.	.	.	2	13.3	1	6.7
		1-4	168	.	.	2	1.2	7	4.2	2	1.2
		5-9	256	.	.	2	0.8	6	2.4	.	.
		10-14	125	.	.	.	.	5	4.1	.	.
		15-20	35	.	.	.	.	1	3.1	.	.
Females	**All cases**		**383**	**.**	**.**	**1**	**0.3**	**10**	**2.6**	**3**	**0.8**
	Age at baseline	<18	92	.	.	.	.	4	4.3	1	1.1
		18-19	33	.	.	.	.	.	.	.	.
		20-24	98	.	.	.	.	4	4.1	.	.
		25-29	91	.	.	.	.	1	1.1	.	.
		30-34	56	.	.	.	.	1	1.8	2	3.6
		35+	13	.	.	1	7.7	.	.	.	.
	Years since diagnosis	5-9	47	.	.	.	.	3	6.4	.	.
		10-14	137	.	.	.	.	4	2.9	1	0.7
		15-19	118	.	.	.	.	1	0.9	2	1.7
		20+	81	.	.	1	1.2	2	2.5	.	.
	Age at diagnosis	<1	7	.	.	.	.	1	14.3	.	.
		1-4	112	.	.	.	.	2	1.8	1	0.9
		5-9	146	.	.	1	0.7	5	3.4	.	.
		10-14	95	.	.	.	.	1	1.1	2	2.1
		15-20	23	.	.	.	.	1	4.3	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2839**	**29**	**1.0**	**.**	**.**	**95**	**3.4**	**2**	**0.1**
	Age at baseline	<18	55	.	.	.	.	2	3.6	.	.
		18-19	54	.	.	.	.	3	5.6	.	.
		20-24	330	3	0.9	.	.	10	3.1	1	0.3
		25-29	734	9	1.2	.	.	25	3.4	.	.
		30-34	867	9	1.1	.	.	33	3.9	1	0.1
		35+	799	8	1.0	.	.	22	2.8	.	.
	Years since diagnosis	5-9	222	1	0.5	.	.	12	5.5	1	0.5
		10-14	866	5	0.6	.	.	31	3.6	.	.
		15-19	933	11	1.2	.	.	25	2.7	.	.
		20+	818	12	1.5	.	.	27	3.3	1	0.1
	Age at diagnosis	1-4	70	.	.	.	.	.	.	.	.
		5-9	356	5	1.4	.	.	6	1.7	1	0.3
		10-14	1029	17	1.7	.	.	46	4.5	.	.
		15-20	1384	7	0.5	.	.	43	3.2	1	0.1
Males	**All cases**		**1468**	**13**	**0.9**	**.**	**.**	**56**	**3.9**	**1**	**0.1**
	Age at baseline	<18	42	.	.	.	.	1	2.4	.	.
		18-19	43	.	.	.	.	2	4.7	.	.
		20-24	210	2	1.0	.	.	7	3.4	.	.
		25-29	402	4	1.0	.	.	13	3.3	.	.
		30-34	433	5	1.2	.	.	23	5.4	1	0.2
		35+	338	2	0.6	.	.	10	3.0	.	.
	Years since diagnosis	5-9	127	1	0.8	.	.	9	7.3	.	.
		10-14	440	1	0.2	.	.	17	3.9	.	.
		15-19	495	8	1.6	.	.	16	3.3	.	.
		20+	406	3	0.7	.	.	14	3.5	1	0.2
	Age at diagnosis	1-4	52	.	.	.	.	.	.	.	.
		5-9	261	4	1.5	.	.	2	0.8	1	0.4
		10-14	525	5	1.0	.	.	25	4.8	.	.
		15-20	630	4	0.6	.	.	29	4.7	.	.
Females	**All cases**		**1371**	**16**	**1.2**	**.**	**.**	**39**	**2.9**	**1**	**0.1**
	Age at baseline	<18	13	.	.	.	.	1	7.7	.	.
		18-19	11	.	.	.	.	1	9.1	.	.
		20-24	120	1	0.8	.	.	3	2.5	1	0.8
		25-29	332	5	1.5	.	.	12	3.6	.	.
		30-34	434	4	0.9	.	.	10	2.4	.	.
		35+	461	6	1.3	.	.	12	2.6	.	.
	Years since diagnosis	5-9	95	.	.	.	.	3	3.2	1	1.1
		10-14	426	4	1.0	.	.	14	3.3	.	.
		15-19	438	3	0.7	.	.	9	2.1	.	.
		20+	412	9	2.2	.	.	13	3.2	.	.
	Age at diagnosis	1-4	18	.	.	.	.	.	.	.	.
		5-9	95	1	1.1	.	.	4	4.2	.	.
		10-14	504	12	2.4	.	.	21	4.2	.	.
		15-20	754	3	0.4	.	.	14	1.9	1	0.1

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2839**	**.**	**.**	**4**	**0.1**	**179**	**6.4**	**1**	**0.0**
	Age at baseline	<18	55	.	.	.	.	7	12.7	.	.
		18-19	54	.	.	.	.	4	7.4	.	.
		20-24	330	.	.	.	.	21	6.5	.	.
		25-29	734	.	.	1	0.1	87	12.0	.	.
		30-34	867	.	.	2	0.2	50	5.8	.	.
		35+	799	.	.	1	0.1	10	1.3	1	0.1
	Years since diagnosis	5-9	222	.	.	.	.	19	8.7	.	.
		10-14	866	.	.	2	0.2	94	11.0	.	.
		15-19	933	.	.	.	.	60	6.5	.	.
		20+	818	.	.	2	0.2	6	0.7	1	0.1
	Age at diagnosis	1-4	70	.	.	.	.	4	5.8	.	.
		5-9	356	.	.	.	.	25	7.1	.	.
		10-14	1029	.	.	1	0.1	59	5.8	.	.
		15-20	1384	.	.	3	0.2	91	6.7	1	0.1
Males	**All cases**		**1468**	**.**	**.**	**3**	**0.2**	**99**	**6.8**	**1**	**0.1**
	Age at baseline	<18	42	.	.	.	.	6	14.3	.	.
		18-19	43	.	.	.	.	3	7.0	.	.
		20-24	210	.	.	.	.	15	7.3	.	.
		25-29	402	.	.	1	0.3	45	11.3	.	.
		30-34	433	.	.	1	0.2	27	6.3	.	.
		35+	338	.	.	1	0.3	3	0.9	1	0.3
	Years since diagnosis	5-9	127	.	.	.	.	12	9.7	.	.
		10-14	440	.	.	1	0.2	48	11.0	.	.
		15-19	495	.	.	.	.	35	7.2	.	.
		20+	406	.	.	2	0.5	4	1.0	1	0.2
	Age at diagnosis	1-4	52	.	.	.	.	4	7.8	.	.
		5-9	261	.	.	.	.	19	7.3	.	.
		10-14	525	.	.	1	0.2	33	6.4	.	.
		15-20	630	.	.	2	0.3	43	6.9	1	0.2
Females	**All cases**		**1371**	**.**	**.**	**1**	**0.1**	**80**	**5.9**	**.**	**.**
	Age at baseline	<18	13	.	.	.	.	1	7.7	.	.
		18-19	11	.	.	.	.	1	9.1	.	.
		20-24	120	.	.	.	.	6	5.0	.	.
		25-29	332	.	.	.	.	42	12.8	.	.
		30-34	434	.	.	1	0.2	23	5.4	.	.
		35+	461	.	.	.	.	7	1.5	.	.
	Years since diagnosis	5-9	95	.	.	.	.	7	7.4	.	.
		10-14	426	.	.	1	0.2	46	11.0	.	.
		15-19	438	.	.	.	.	25	5.8	.	.
		20+	412	.	.	.	.	2	0.5	.	.
	Age at diagnosis	1-4	18	.	.	.	.	.	.	.	.
		5-9	95	.	.	.	.	6	6.3	.	.
		10-14	504	.	.	.	.	26	5.2	.	.
		15-20	754	.	.	1	0.1	48	6.5	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1933**	**9**	**0.5**	**1**	**0.1**	**1118**	**58.4**	**1**	**0.1**
	Age at baseline	<18	200	2	1.0	.	.	134	67.7	1	0.5
		18-19	119	1	0.8	.	.	79	66.9	.	.
		20-24	409	1	0.2	.	.	245	60.3	.	.
		25-29	533	4	0.8	1	0.2	314	59.8	.	.
		30-34	443	.	.	.	.	251	56.9	.	.
		35+	229	1	0.4	.	.	95	42.0	.	.
	Years since diagnosis	5-9	132	2	1.5	.	.	81	61.8	.	.
		10-14	608	3	0.5	1	0.2	359	59.4	1	0.2
		15-19	665	3	0.5	.	.	403	61.2	.	.
		20+	528	1	0.2	.	.	275	52.9	.	.
	Age at diagnosis	<1	12	.	.	.	.	6	50.0	.	.
		1-4	320	2	0.6	.	.	209	66.8	1	0.3
		5-9	588	3	0.5	.	.	359	61.6	.	.
		10-14	604	3	0.5	1	0.2	344	57.1	.	.
		15-20	409	1	0.2	.	.	200	49.5	.	.
Males	**All cases**		**1304**	**6**	**0.5**	**1**	**0.1**	**754**	**58.4**	**.**	**.**
	Age at baseline	<18	138	2	1.5	.	.	93	68.4	.	.
		18-19	87	1	1.2	.	.	54	62.8	.	.
		20-24	268	.	.	.	.	164	61.4	.	.
		25-29	372	3	0.8	1	0.3	221	60.2	.	.
		30-34	291	.	.	.	.	164	56.7	.	.
		35+	148	.	.	.	.	58	39.5	.	.
	Years since diagnosis	5-9	99	2	2.0	.	.	61	62.2	.	.
		10-14	412	2	0.5	1	0.2	248	60.6	.	.
		15-19	433	2	0.5	.	.	261	60.7	.	.
		20+	360	.	.	.	.	184	51.8	.	.
	Age at diagnosis	<1	3	.	.	.	.	.	.	.	.
		1-4	215	1	0.5	.	.	142	67.6	.	.
		5-9	411	2	0.5	.	.	248	60.9	.	.
		10-14	412	3	0.7	1	0.2	238	57.8	.	.
		15-20	263	.	.	.	.	126	48.5	.	.
Females	**All cases**		**629**	**3**	**0.5**	**.**	**.**	**364**	**58.5**	**1**	**0.2**
	Age at baseline	<18	62	.	.	.	.	41	66.1	1	1.6
		18-19	32	.	.	.	.	25	78.1	.	.
		20-24	141	1	0.7	.	.	81	58.3	.	.
		25-29	161	1	0.6	.	.	93	58.9	.	.
		30-34	152	.	.	.	.	87	57.2	.	.
		35+	81	1	1.3	.	.	37	46.8	.	.
	Years since diagnosis	5-9	33	.	.	.	.	20	60.6	.	.
		10-14	196	1	0.5	.	.	111	56.9	1	0.5
		15-19	232	1	0.4	.	.	142	62.0	.	.
		20+	168	1	0.6	.	.	91	55.2	.	.
	Age at diagnosis	<1	9	.	.	.	.	6	66.7	.	.
		1-4	105	1	1.0	.	.	67	65.0	1	1.0
		5-9	177	1	0.6	.	.	111	63.1	.	.
		10-14	192	.	.	.	.	106	55.8	.	.
		15-20	146	1	0.7	.	.	74	51.4	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1933**	**2**	**0.1**	**481**	**25.1**	**1661**	**87.0**	**353**	**18.4**
	Age at baseline	<18	200	.	.	44	22.1	180	91.4	42	21.1
		18-19	119	.	.	28	23.7	111	94.1	29	24.6
		20-24	409	1	0.2	107	26.3	368	90.4	72	17.7
		25-29	533	.	.	134	25.5	466	89.3	97	18.4
		30-34	443	1	0.2	115	26.1	376	85.5	80	18.1
		35+	229	.	.	53	23.5	160	70.8	33	14.6
	Years since diagnosis	5-9	132	.	.	32	24.4	112	85.5	22	16.7
		10-14	608	.	.	152	25.2	531	88.4	122	20.2
		15-19	665	2	0.3	171	25.9	593	90.1	119	18.1
		20+	528	.	.	126	24.1	425	81.7	90	17.2
	Age at diagnosis	<1	12	.	.	5	41.7	9	75.0	3	25.0
		1-4	320	1	0.3	61	19.4	284	91.0	71	22.5
		5-9	588	.	.	155	26.5	522	89.5	102	17.5
		10-14	604	1	0.2	166	27.7	546	91.0	122	20.3
		15-20	409	.	.	94	23.3	300	74.4	55	13.6
Males	**All cases**		**1304**	**1**	**0.1**	**307**	**23.7**	**1125**	**87.2**	**228**	**17.6**
	Age at baseline	<18	138	.	.	29	21.2	125	92.6	26	19.0
		18-19	87	.	.	16	18.6	82	95.3	24	27.9
		20-24	268	1	0.4	67	25.1	244	91.4	43	16.0
		25-29	372	.	.	87	23.7	329	89.9	67	18.2
		30-34	291	.	.	74	25.6	244	84.4	49	16.9
		35+	148	.	.	34	23.1	101	68.7	19	12.9
	Years since diagnosis	5-9	99	.	.	25	25.5	86	87.8	18	18.2
		10-14	412	.	.	99	24.1	369	90.4	82	20.0
		15-19	433	1	0.2	100	23.3	388	90.2	71	16.5
		20+	360	.	.	83	23.4	282	79.7	57	16.0
	Age at diagnosis	<1	3	.	.	1	33.3	1	33.3	.	.
		1-4	215	1	0.5	33	15.6	188	90.4	46	21.7
		5-9	411	.	.	102	25.0	367	90.2	68	16.7
		10-14	412	.	.	111	27.0	379	92.0	83	20.1
		15-20	263	.	.	60	23.1	190	73.1	31	11.9
Females	**All cases**		**629**	**1**	**0.2**	**174**	**27.9**	**536**	**86.5**	**125**	**20.1**
	Age at baseline	<18	62	.	.	15	24.2	55	88.7	16	25.8
		18-19	32	.	.	12	37.5	29	90.6	5	15.6
		20-24	141	.	.	40	28.6	124	88.6	29	20.9
		25-29	161	.	.	47	29.7	137	87.8	30	19.0
		30-34	152	1	0.7	41	27.0	132	87.4	31	20.5
		35+	81	.	.	19	24.1	59	74.7	14	17.7
	Years since diagnosis	5-9	33	.	.	7	21.2	26	78.8	4	12.1
		10-14	196	.	.	53	27.3	162	83.9	40	20.6
		15-19	232	1	0.4	71	31.0	205	89.9	48	21.1
		20+	168	.	.	43	25.7	143	86.1	33	19.9
	Age at diagnosis	<1	9	.	.	4	44.4	8	88.9	3	33.3
		1-4	105	.	.	28	26.9	96	92.3	25	24.0
		5-9	177	.	.	53	29.9	155	88.1	34	19.3
		10-14	192	1	0.5	55	29.1	167	88.8	39	20.6
		15-20	146	.	.	34	23.6	110	76.9	24	16.8

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2087**	**3**	**0.1**	**.**	**.**	**4**	**0.2**	**5**	**0.2**
	Age at baseline	<18	762	1	0.1	.	.	.	.	2	0.3
		18-19	276	1	0.4	.	.	.	.	.	.
		20-24	616	.	.	.	.	1	0.2	3	0.5
		25-29	347	1	0.3	.	.	3	0.9	.	.
		30-34	69	.	.	.	.	.	.	.	.
		35+	17	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	168	.	.	.	.	.	.	1	0.6
		10-14	674	2	0.3	.	.	.	.	2	0.3
		15-19	685	1	0.1	.	.	1	0.1	2	0.3
		20+	560	.	.	.	.	3	0.5	.	.
	Age at diagnosis	<1	305	.	.	.	.	.	.	.	.
		1-4	1270	1	0.1	.	.	2	0.2	2	0.2
		5-9	436	2	0.5	.	.	2	0.5	2	0.5
		10-14	56	.	.	.	.	.	.	.	.
		15-20	20	.	.	.	.	.	.	1	5.0
Males	**All cases**		**924**	**1**	**0.1**	**.**	**.**	**3**	**0.3**	**3**	**0.3**
	Age at baseline	<18	370	1	0.3	.	.	.	.	2	0.5
		18-19	111	.	.	.	.	.	.	.	.
		20-24	255	.	.	.	.	.	.	1	0.4
		25-29	152	.	.	.	.	3	2.0	.	.
		30-34	29	.	.	.	.	.	.	.	.
		35+	7	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	75	.	.	.	.	.	.	.	.
		10-14	306	1	0.3	.	.	.	.	2	0.7
		15-19	292	.	.	.	.	.	.	1	0.3
		20+	251	.	.	.	.	3	1.2	.	.
	Age at diagnosis	<1	152	.	.	.	.	.	.	.	.
		1-4	567	1	0.2	.	.	2	0.4	1	0.2
		5-9	177	.	.	.	.	1	0.6	2	1.1
		10-14	20	.	.	.	.	.	.	.	.
		15-20	8	.	.	.	.	.	.	.	.
Females	**All cases**		**1163**	**2**	**0.2**	**.**	**.**	**1**	**0.1**	**2**	**0.2**
	Age at baseline	<18	392	.	.	.	.	.	.	.	.
		18-19	165	1	0.6	.	.	.	.	.	.
		20-24	361	.	.	.	.	1	0.3	2	0.6
		25-29	195	1	0.5	.	.	.	.	.	.
		30-34	40	.	.	.	.	.	.	.	.
		35+	10	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	93	.	.	.	.	.	.	1	1.1
		10-14	368	1	0.3	.	.	.	.	.	.
		15-19	393	1	0.3	.	.	1	0.3	1	0.3
		20+	309	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	153	.	.	.	.	.	.	.	.
		1-4	703	.	.	.	.	.	.	1	0.1
		5-9	259	2	0.8	.	.	1	0.4	.	.
		10-14	36	.	.	.	.	.	.	.	.
		15-20	12	.	.	.	.	.	.	1	8.3

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**2087**	**.**	**.**	**1**	**0.0**	**1**	**0.0**	**1**	**0.0**
	Age at baseline	<18	762	.	.	.	.	.	.	1	0.1
		18-19	276	.	.	.	.	.	.	.	.
		20-24	616	.	.	1	0.2	1	0.2	.	.
		25-29	347	.	.	.	.	.	.	.	.
		30-34	69	.	.	.	.	.	.	.	.
		35+	17	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	168	.	.	.	.	.	.	.	.
		10-14	674	.	.	.	.	.	.	1	0.1
		15-19	685	.	.	1	0.1	1	0.1	.	.
		20+	560	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	305	.	.	.	.	.	.	.	.
		1-4	1270	.	.	1	0.1	.	.	.	.
		5-9	436	.	.	.	.	1	0.2	1	0.2
		10-14	56	.	.	.	.	.	.	.	.
		15-20	20	.	.	.	.	.	.	.	.
Males	**All cases**		**924**	**.**	**.**	**.**	**.**	**.**	**.**	**.**	**.**
	Age at baseline	<18	370	.	.	.	.	.	.	.	.
		18-19	111	.	.	.	.	.	.	.	.
		20-24	255	.	.	.	.	.	.	.	.
		25-29	152	.	.	.	.	.	.	.	.
		30-34	29	.	.	.	.	.	.	.	.
		35+	7	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	75	.	.	.	.	.	.	.	.
		10-14	306	.	.	.	.	.	.	.	.
		15-19	292	.	.	.	.	.	.	.	.
		20+	251	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	152	.	.	.	.	.	.	.	.
		1-4	567	.	.	.	.	.	.	.	.
		5-9	177	.	.	.	.	.	.	.	.
		10-14	20	.	.	.	.	.	.	.	.
		15-20	8	.	.	.	.	.	.	.	.
Females	**All cases**		**1163**	**.**	**.**	**1**	**0.1**	**1**	**0.1**	**1**	**0.1**
	Age at baseline	<18	392	.	.	.	.	.	.	1	0.3
		18-19	165	.	.	.	.	.	.	.	.
		20-24	361	.	.	1	0.3	1	0.3	.	.
		25-29	195	.	.	.	.	.	.	.	.
		30-34	40	.	.	.	.	.	.	.	.
		35+	10	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	93	.	.	.	.	.	.	.	.
		10-14	368	.	.	.	.	.	.	1	0.3
		15-19	393	.	.	1	0.3	1	0.3	.	.
		20+	309	.	.	.	.	.	.	.	.
	Age at diagnosis	<1	153	.	.	.	.	.	.	.	.
		1-4	703	.	.	1	0.1	.	.	.	.
		5-9	259	.	.	.	.	1	0.4	1	0.4
		10-14	36	.	.	.	.	.	.	.	.
		15-20	12	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1811**	**1**	**0.1**	**.**	**.**	**21**	**1.2**	**6**	**0.3**
	Age at baseline	<18	890	.	.	.	.	11	1.2	6	0.7
		18-19	216	.	.	.	.	1	0.5	.	.
		20-24	511	1	0.2	.	.	5	1.0	.	.
		25-29	154	.	.	.	.	2	1.3	.	.
		30-34	34	.	.	.	.	2	6.3	.	.
		35+	6	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	152	.	.	.	.	4	2.7	1	0.7
		10-14	559	.	.	.	.	6	1.1	4	0.7
		15-19	594	.	.	.	.	4	0.7	1	0.2
		20+	506	1	0.2	.	.	7	1.4	.	.
	Age at diagnosis	<1	917	1	0.1	.	.	11	1.2	4	0.4
		1-4	713	.	.	.	.	8	1.1	2	0.3
		5-9	137	.	.	.	.	1	0.7	.	.
		10-14	27	.	.	.	.	1	3.8	.	.
		15-20	17	.	.	.	.	.	.	.	.
Males	**All cases**		**876**	**1**	**0.1**	**.**	**.**	**9**	**1.0**	**1**	**0.1**
	Age at baseline	<18	441	.	.	.	.	4	0.9	1	0.2
		18-19	94	.	.	.	.	.	.	.	.
		20-24	259	1	0.4	.	.	3	1.2	.	.
		25-29	66	.	.	.	.	.	.	.	.
		30-34	14	.	.	.	.	2	14.3	.	.
		35+	2	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	72	.	.	.	.	3	4.2	1	1.4
		10-14	275	.	.	.	.	.	.	.	.
		15-19	284	.	.	.	.	2	0.7	.	.
		20+	245	1	0.4	.	.	4	1.7	.	.
	Age at diagnosis	<1	472	1	0.2	.	.	4	0.9	.	.
		1-4	320	.	.	.	.	5	1.6	1	0.3
		5-9	68	.	.	.	.	.	.	.	.
		10-14	10	.	.	.	.	.	.	.	.
		15-20	6	.	.	.	.	.	.	.	.
Females	**All cases**		**935**	**.**	**.**	**.**	**.**	**12**	**1.3**	**5**	**0.5**
	Age at baseline	<18	449	.	.	.	.	7	1.6	5	1.1
		18-19	122	.	.	.	.	1	0.8	.	.
		20-24	252	.	.	.	.	2	0.8	.	.
		25-29	88	.	.	.	.	2	2.3	.	.
		30-34	20	.	.	.	.	.	.	.	.
		35+	4	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	80	.	.	.	.	1	1.3	.	.
		10-14	284	.	.	.	.	6	2.1	4	1.4
		15-19	310	.	.	.	.	2	0.7	1	0.3
		20+	261	.	.	.	.	3	1.2	.	.
	Age at diagnosis	<1	445	.	.	.	.	7	1.6	4	0.9
		1-4	393	.	.	.	.	3	0.8	1	0.3
		5-9	69	.	.	.	.	1	1.5	.	.
		10-14	17	.	.	.	.	1	6.3	.	.
		15-20	11	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1811**	**1**	**0.1**	**1**	**0.1**	**20**	**1.1**	**.**	**.**
	Age at baseline	<18	890	.	.	1	0.1	12	1.4	.	.
		18-19	216	.	.	.	.	.	.	.	.
		20-24	511	1	0.2	.	.	3	0.6	.	.
		25-29	154	.	.	.	.	5	3.3	.	.
		30-34	34	.	.	.	.	.	.	.	.
		35+	6	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	152	.	.	1	0.7	6	4.0	.	.
		10-14	559	.	.	.	.	5	0.9	.	.
		15-19	594	1	0.2	.	.	4	0.7	.	.
		20+	506	.	.	.	.	5	1.0	.	.
	Age at diagnosis	<1	917	.	.	.	.	3	0.3	.	.
		1-4	713	1	0.1	1	0.1	13	1.8	.	.
		5-9	137	.	.	.	.	3	2.2	.	.
		10-14	27	.	.	.	.	1	3.8	.	.
		15-20	17	.	.	.	.	.	.	.	.
Males	**All cases**		**876**	**1**	**0.1**	**1**	**0.1**	**10**	**1.2**	**.**	**.**
	Age at baseline	<18	441	.	.	1	0.2	7	1.6	.	.
		18-19	94	.	.	.	.	.	.	.	.
		20-24	259	1	0.4	.	.	1	0.4	.	.
		25-29	66	.	.	.	.	2	3.1	.	.
		30-34	14	.	.	.	.	.	.	.	.
		35+	2	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	72	.	.	1	1.4	4	5.6	.	.
		10-14	275	.	.	.	.	1	0.4	.	.
		15-19	284	1	0.4	.	.	2	0.7	.	.
		20+	245	.	.	.	.	3	1.2	.	.
	Age at diagnosis	<1	472	.	.	.	.	2	0.4	.	.
		1-4	320	1	0.3	1	0.3	6	1.9	.	.
		5-9	68	.	.	.	.	2	3.0	.	.
		10-14	10	.	.	.	.	.	.	.	.
		15-20	6	.	.	.	.	.	.	.	.
Females	**All cases**		**935**	**.**	**.**	**.**	**.**	**10**	**1.1**	**.**	**.**
	Age at baseline	<18	449	.	.	.	.	5	1.1	.	.
		18-19	122	.	.	.	.	.	.	.	.
		20-24	252	.	.	.	.	2	0.8	.	.
		25-29	88	.	.	.	.	3	3.5	.	.
		30-34	20	.	.	.	.	.	.	.	.
		35+	4	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	80	.	.	.	.	2	2.5	.	.
		10-14	284	.	.	.	.	4	1.4	.	.
		15-19	310	.	.	.	.	2	0.7	.	.
		20+	261	.	.	.	.	2	0.8	.	.
	Age at diagnosis	<1	445	.	.	.	.	1	0.2	.	.
		1-4	393	.	.	.	.	7	1.8	.	.
		5-9	69	.	.	.	.	1	1.5	.	.
		10-14	17	.	.	.	.	1	6.3	.	.
		15-20	11	.	.	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1596**	**5**	**0.3**	**.**	**.**	**70**	**4.4**	**7**	**0.4**
	Age at baseline	<18	313	.	.	.	.	29	9.3	2	0.6
		18-19	115	2	1.8	.	.	5	4.4	.	.
		20-24	383	2	0.5	.	.	14	3.7	1	0.3
		25-29	354	1	0.3	.	.	15	4.3	1	0.3
		30-34	267	.	.	.	.	6	2.3	1	0.4
		35+	164	.	.	.	.	1	0.6	2	1.2
	Years since diagnosis	5-9	165	.	.	.	.	14	8.5	.	.
		10-14	473	2	0.4	.	.	31	6.6	2	0.4
		15-19	499	2	0.4	.	.	10	2.0	3	0.6
		20+	459	1	0.2	.	.	15	3.3	2	0.4
	Age at diagnosis	<1	108	.	.	.	.	3	2.8	.	.
		1-4	513	2	0.4	.	.	29	5.7	2	0.4
		5-9	361	3	0.8	.	.	25	6.9	1	0.3
		10-14	313	.	.	.	.	8	2.6	3	1.0
		15-20	301	.	.	.	.	5	1.7	1	0.3
Males	**All cases**		**853**	**2**	**0.2**	**.**	**.**	**42**	**4.9**	**3**	**0.4**
	Age at baseline	<18	179	.	.	.	.	16	8.9	1	0.6
		18-19	58	1	1.7	.	.	3	5.2	.	.
		20-24	214	.	.	.	.	7	3.3	.	.
		25-29	182	1	0.6	.	.	10	5.5	.	.
		30-34	141	.	.	.	.	5	3.6	1	0.7
		35+	79	.	.	.	.	1	1.3	1	1.3
	Years since diagnosis	5-9	89	.	.	.	.	9	10.1	.	.
		10-14	264	1	0.4	.	.	17	6.4	1	0.4
		15-19	253	.	.	.	.	5	2.0	1	0.4
		20+	247	1	0.4	.	.	11	4.5	1	0.4
	Age at diagnosis	<1	44	.	.	.	.	2	4.5	.	.
		1-4	298	1	0.3	.	.	16	5.4	1	0.3
		5-9	203	1	0.5	.	.	13	6.4	.	.
		10-14	167	.	.	.	.	7	4.2	1	0.6
		15-20	141	.	.	.	.	4	2.8	1	0.7
Females	**All cases**		**743**	**3**	**0.4**	**.**	**.**	**28**	**3.8**	**4**	**0.5**
	Age at baseline	<18	134	.	.	.	.	13	9.8	1	0.8
		18-19	57	1	1.8	.	.	2	3.6	.	.
		20-24	169	2	1.2	.	.	7	4.2	1	0.6
		25-29	172	.	.	.	.	5	2.9	1	0.6
		30-34	126	.	.	.	.	1	0.8	.	.
		35+	85	.	.	.	.	.	.	1	1.2
	Years since diagnosis	5-9	76	.	.	.	.	5	6.7	.	.
		10-14	209	1	0.5	.	.	14	6.8	1	0.5
		15-19	246	2	0.8	.	.	5	2.0	2	0.8
		20+	212	.	.	.	.	4	1.9	1	0.5
	Age at diagnosis	<1	64	.	.	.	.	1	1.6	.	.
		1-4	215	1	0.5	.	.	13	6.1	1	0.5
		5-9	158	2	1.3	.	.	12	7.6	1	0.6
		10-14	146	.	.	.	.	1	0.7	2	1.4
		15-20	160	.	.	.	.	1	0.6	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1596**	**1**	**0.1**	**4**	**0.3**	**135**	**8.5**	**.**	**.**
	Age at baseline	<18	313	.	.	1	0.3	30	9.6	.	.
		18-19	115	.	.	.	.	9	7.9	.	.
		20-24	383	1	0.3	1	0.3	26	6.8	.	.
		25-29	354	.	.	2	0.6	33	9.5	.	.
		30-34	267	.	.	.	.	21	7.9	.	.
		35+	164	.	.	.	.	16	9.9	.	.
	Years since diagnosis	5-9	165	.	.	1	0.6	21	12.9	.	.
		10-14	473	1	0.2	2	0.4	47	10.0	.	.
		15-19	499	.	.	1	0.2	30	6.0	.	.
		20+	459	.	.	.	.	37	8.1	.	.
	Age at diagnosis	<1	108	.	.	.	.	3	2.8	.	.
		1-4	513	.	.	1	0.2	37	7.3	.	.
		5-9	361	.	.	1	0.3	34	9.4	.	.
		10-14	313	1	0.3	2	0.6	30	9.7	.	.
		15-20	301	.	.	.	.	31	10.4	.	.
Males	**All cases**		**853**	**1**	**0.1**	**2**	**0.2**	**76**	**9.0**	**.**	**.**
	Age at baseline	<18	179	.	.	1	0.6	18	10.1	.	.
		18-19	58	.	.	.	.	6	10.3	.	.
		20-24	214	1	0.5	.	.	11	5.2	.	.
		25-29	182	.	.	1	0.6	21	11.7	.	.
		30-34	141	.	.	.	.	12	8.6	.	.
		35+	79	.	.	.	.	8	10.1	.	.
	Years since diagnosis	5-9	89	.	.	.	.	11	12.5	.	.
		10-14	264	1	0.4	2	0.8	29	11.0	.	.
		15-19	253	.	.	.	.	14	5.6	.	.
		20+	247	.	.	.	.	22	8.9	.	.
	Age at diagnosis	<1	44	.	.	.	.	.	.	.	.
		1-4	298	.	.	1	0.3	24	8.1	.	.
		5-9	203	.	.	.	.	17	8.4	.	.
		10-14	167	1	0.6	1	0.6	21	12.7	.	.
		15-20	141	.	.	.	.	14	10.1	.	.
Females	**All cases**		**743**	**.**	**.**	**2**	**0.3**	**59**	**8.0**	**.**	**.**
	Age at baseline	<18	134	.	.	.	.	12	9.1	.	.
		18-19	57	.	.	.	.	3	5.4	.	.
		20-24	169	.	.	1	0.6	15	8.9	.	.
		25-29	172	.	.	1	0.6	12	7.1	.	.
		30-34	126	.	.	.	.	9	7.1	.	.
		35+	85	.	.	.	.	8	9.6	.	.
	Years since diagnosis	5-9	76	.	.	1	1.3	10	13.3	.	.
		10-14	209	.	.	.	.	18	8.7	.	.
		15-19	246	.	.	1	0.4	16	6.5	.	.
		20+	212	.	.	.	.	15	7.2	.	.
	Age at diagnosis	<1	64	.	.	.	.	3	4.8	.	.
		1-4	215	.	.	.	.	13	6.1	.	.
		5-9	158	.	.	1	0.6	17	10.8	.	.
		10-14	146	.	.	1	0.7	9	6.3	.	.
		15-20	160	.	.	.	.	17	10.8	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1937**	**2**	**0.1**	**.**	**.**	**18**	**0.9**	**11**	**0.6**
	Age at baseline	<18	85	.	.	.	.	2	2.4	1	1.2
		18-19	66	.	.	.	.	3	4.5	.	.
		20-24	360	.	.	.	.	7	1.9	1	0.3
		25-29	528	.	.	.	.	2	0.4	3	0.6
		30-34	521	2	0.4	.	.	2	0.4	5	1.0
		35+	377	.	.	.	.	2	0.5	1	0.3
	Years since diagnosis	5-9	216	.	.	.	.	6	2.8	.	.
		10-14	630	.	.	.	.	4	0.6	4	0.6
		15-19	635	2	0.3	.	.	4	0.6	6	0.9
		20+	456	.	.	.	.	4	0.9	1	0.2
	Age at diagnosis	<1	8	.	.	.	.	.	.	.	.
		1-4	80	.	.	.	.	2	2.5	1	1.3
		5-9	337	.	.	.	.	6	1.8	1	0.3
		10-14	776	.	.	.	.	6	0.8	3	0.4
		15-20	736	2	0.3	.	.	4	0.5	6	0.8
Males	**All cases**		**983**	**1**	**0.1**	**.**	**.**	**7**	**0.7**	**6**	**0.6**
	Age at baseline	<18	43	.	.	.	.	1	2.3	.	.
		18-19	33	.	.	.	.	2	6.1	.	.
		20-24	175	.	.	.	.	2	1.1	.	.
		25-29	274	.	.	.	.	1	0.4	1	0.4
		30-34	258	1	0.4	.	.	.	.	4	1.6
		35+	200	.	.	.	.	1	0.5	1	0.5
	Years since diagnosis	5-9	115	.	.	.	.	4	3.5	.	.
		10-14	319	.	.	.	.	1	0.3	3	0.9
		15-19	323	1	0.3	.	.	1	0.3	2	0.6
		20+	226	.	.	.	.	1	0.4	1	0.4
	Age at diagnosis	<1	4	.	.	.	.	.	.	.	.
		1-4	41	.	.	.	.	.	.	.	.
		5-9	172	.	.	.	.	2	1.2	.	.
		10-14	364	.	.	.	.	3	0.8	1	0.3
		15-20	402	1	0.3	.	.	2	0.5	5	1.3
Females	**All cases**		**954**	**1**	**0.1**	**.**	**.**	**11**	**1.2**	**5**	**0.5**
	Age at baseline	<18	42	.	.	.	.	1	2.4	1	2.4
		18-19	33	.	.	.	.	1	3.0	.	.
		20-24	185	.	.	.	.	5	2.7	1	0.5
		25-29	254	.	.	.	.	1	0.4	2	0.8
		30-34	263	1	0.4	.	.	2	0.8	1	0.4
		35+	177	.	.	.	.	1	0.6	.	.
	Years since diagnosis	5-9	101	.	.	.	.	2	2.0	.	.
		10-14	311	.	.	.	.	3	1.0	1	0.3
		15-19	312	1	0.3	.	.	3	1.0	4	1.3
		20+	230	.	.	.	.	3	1.3	.	.
	Age at diagnosis	<1	4	.	.	.	.	.	.	.	.
		1-4	39	.	.	.	.	2	5.1	1	2.6
		5-9	165	.	.	.	.	4	2.4	1	0.6
		10-14	412	.	.	.	.	3	0.7	2	0.5
		15-20	334	1	0.3	.	.	2	0.6	1	0.3

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1937**	**1**	**0.1**	**.**	**.**	**975**	**50.7**	**1**	**0.1**
	Age at baseline	<18	85	.	.	.	.	26	30.6	.	.
		18-19	66	.	.	.	.	29	43.9	.	.
		20-24	360	.	.	.	.	182	50.7	.	.
		25-29	528	.	.	.	.	263	50.4	1	0.2
		30-34	521	1	0.2	.	.	284	54.7	.	.
		35+	377	.	.	.	.	191	51.2	.	.
	Years since diagnosis	5-9	216	.	.	.	.	116	54.0	.	.
		10-14	630	.	.	.	.	311	49.8	.	.
		15-19	635	1	0.2	.	.	336	53.2	1	0.2
		20+	456	.	.	.	.	212	46.9	.	.
	Age at diagnosis	<1	8	.	.	.	.	.	.	.	.
		1-4	80	.	.	.	.	23	28.8	.	.
		5-9	337	.	.	.	.	132	39.3	1	0.3
		10-14	776	1	0.1	.	.	433	56.2	.	.
		15-20	736	.	.	.	.	387	53.1	.	.
Males	**All cases**		**983**	**.**	**.**	**.**	**.**	**505**	**51.7**	**1**	**0.1**
	Age at baseline	<18	43	.	.	.	.	17	39.5	.	.
		18-19	33	.	.	.	.	14	42.4	.	.
		20-24	175	.	.	.	.	81	46.6	.	.
		25-29	274	.	.	.	.	137	50.7	1	0.4
		30-34	258	.	.	.	.	145	56.4	.	.
		35+	200	.	.	.	.	111	55.8	.	.
	Years since diagnosis	5-9	115	.	.	.	.	59	51.8	.	.
		10-14	319	.	.	.	.	162	51.3	.	.
		15-19	323	.	.	.	.	172	53.4	1	0.3
		20+	226	.	.	.	.	112	50.0	.	.
	Age at diagnosis	<1	4	.	.	.	.	.	.	.	.
		1-4	41	.	.	.	.	12	29.3	.	.
		5-9	172	.	.	.	.	68	39.8	1	0.6
		10-14	364	.	.	.	.	200	55.4	.	.
		15-20	402	.	.	.	.	225	56.4	.	.
Females	**All cases**		**954**	**1**	**0.1**	**.**	**.**	**470**	**49.6**	**.**	**.**
	Age at baseline	<18	42	.	.	.	.	9	21.4	.	.
		18-19	33	.	.	.	.	15	45.5	.	.
		20-24	185	.	.	.	.	101	54.6	.	.
		25-29	254	.	.	.	.	126	50.0	.	.
		30-34	263	1	0.4	.	.	139	53.1	.	.
		35+	177	.	.	.	.	80	46.0	.	.
	Years since diagnosis	5-9	101	.	.	.	.	57	56.4	.	.
		10-14	311	.	.	.	.	149	48.2	.	.
		15-19	312	1	0.3	.	.	164	52.9	.	.
		20+	230	.	.	.	.	100	43.9	.	.
	Age at diagnosis	<1	4	.	.	.	.	.	.	.	.
		1-4	39	.	.	.	.	11	28.2	.	.
		5-9	165	.	.	.	.	64	38.8	.	.
		10-14	412	1	0.2	.	.	233	56.8	.	.
		15-20	334	.	.	.	.	162	49.1	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**686**	**.**	**.**	**.**	**.**	**15**	**2.2**	**9**	**1.3**
	Age at baseline	<18	54	.	.	.	.	2	3.7	1	1.9
		18-19	33	.	.	.	.	3	9.1	.	.
		20-24	157	.	.	.	.	5	3.2	1	0.6
		25-29	193	.	.	.	.	2	1.0	3	1.6
		30-34	154	.	.	.	.	1	0.7	4	2.6
		35+	95	.	.	.	.	2	2.1	.	.
	Years since diagnosis	5-9	91	.	.	.	.	5	5.6	.	.
		10-14	231	.	.	.	.	3	1.3	4	1.7
		15-19	214	.	.	.	.	3	1.4	5	2.3
		20+	150	.	.	.	.	4	2.7	.	.
	Age at diagnosis	<1	4	.	.	.	.	.	.	.	.
		1-4	50	.	.	.	.	2	4.0	1	2.0
		5-9	169	.	.	.	.	6	3.6	1	0.6
		10-14	258	.	.	.	.	4	1.6	3	1.2
		15-20	205	.	.	.	.	3	1.5	4	2.0
Males	**All cases**		**354**	**.**	**.**	**.**	**.**	**6**	**1.7**	**4**	**1.1**
	Age at baseline	<18	24	.	.	.	.	1	4.2	.	.
		18-19	17	.	.	.	.	2	11.8	.	.
		20-24	79	.	.	.	.	1	1.3	.	.
		25-29	99	.	.	.	.	1	1.0	1	1.0
		30-34	83	.	.	.	.	.	.	3	3.6
		35+	52	.	.	.	.	1	1.9	.	.
	Years since diagnosis	5-9	49	.	.	.	.	4	8.3	.	.
		10-14	109	.	.	.	.	.	.	3	2.8
		15-19	116	.	.	.	.	1	0.9	1	0.9
		20+	80	.	.	.	.	1	1.3	.	.
	Age at diagnosis	<1	2	.	.	.	.	.	.	.	.
		1-4	26	.	.	.	.	.	.	.	.
		5-9	83	.	.	.	.	2	2.4	.	.
		10-14	136	.	.	.	.	2	1.5	1	0.7
		15-20	107	.	.	.	.	2	1.9	3	2.8
Females	**All cases**		**332**	**.**	**.**	**.**	**.**	**9**	**2.7**	**5**	**1.5**
	Age at baseline	<18	30	.	.	.	.	1	3.3	1	3.3
		18-19	16	.	.	.	.	1	6.3	.	.
		20-24	78	.	.	.	.	4	5.1	1	1.3
		25-29	94	.	.	.	.	1	1.1	2	2.1
		30-34	71	.	.	.	.	1	1.4	1	1.4
		35+	43	.	.	.	.	1	2.3	.	.
	Years since diagnosis	5-9	42	.	.	.	.	1	2.4	.	.
		10-14	122	.	.	.	.	3	2.5	1	0.8
		15-19	98	.	.	.	.	2	2.1	4	4.1
		20+	70	.	.	.	.	3	4.3	.	.
	Age at diagnosis	<1	2	.	.	.	.	.	.	.	.
		1-4	24	.	.	.	.	2	8.3	1	4.2
		5-9	86	.	.	.	.	4	4.7	1	1.2
		10-14	122	.	.	.	.	2	1.6	2	1.6
		15-20	98	.	.	.	.	1	1.0	1	1.0

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**686**	**.**	**.**	**.**	**.**	**73**	**10.7**	**1**	**0.1**
	Age at baseline	<18	54	.	.	.	.	5	9.3	.	.
		18-19	33	.	.	.	.	6	18.2	.	.
		20-24	157	.	.	.	.	19	12.2	.	.
		25-29	193	.	.	.	.	13	6.7	1	0.5
		30-34	154	.	.	.	.	14	9.2	.	.
		35+	95	.	.	.	.	16	16.8	.	.
	Years since diagnosis	5-9	91	.	.	.	.	13	14.4	.	.
		10-14	231	.	.	.	.	29	12.6	.	.
		15-19	214	.	.	.	.	13	6.1	1	0.5
		20+	150	.	.	.	.	18	12.0	.	.
	Age at diagnosis	<1	4	.	.	.	.	.	.	.	.
		1-4	50	.	.	.	.	4	8.0	.	.
		5-9	169	.	.	.	.	10	5.9	1	0.6
		10-14	258	.	.	.	.	29	11.3	.	.
		15-20	205	.	.	.	.	30	14.7	.	.
Males	**All cases**		**354**	**.**	**.**	**.**	**.**	**38**	**10.8**	**1**	**0.3**
	Age at baseline	<18	24	.	.	.	.	2	8.3	.	.
		18-19	17	.	.	.	.	3	17.6	.	.
		20-24	79	.	.	.	.	10	12.8	.	.
		25-29	99	.	.	.	.	5	5.1	1	1.0
		30-34	83	.	.	.	.	11	13.3	.	.
		35+	52	.	.	.	.	7	13.5	.	.
	Years since diagnosis	5-9	49	.	.	.	.	7	14.6	.	.
		10-14	109	.	.	.	.	13	11.9	.	.
		15-19	116	.	.	.	.	7	6.0	1	0.9
		20+	80	.	.	.	.	11	13.8	.	.
	Age at diagnosis	<1	2	.	.	.	.	.	.	.	.
		1-4	26	.	.	.	.	2	7.7	.	.
		5-9	83	.	.	.	.	6	7.2	1	1.2
		10-14	136	.	.	.	.	15	11.1	.	.
		15-20	107	.	.	.	.	15	14.0	.	.
Females	**All cases**		**332**	**.**	**.**	**.**	**.**	**35**	**10.6**	**.**	**.**
	Age at baseline	<18	30	.	.	.	.	3	10.0	.	.
		18-19	16	.	.	.	.	3	18.8	.	.
		20-24	78	.	.	.	.	9	11.5	.	.
		25-29	94	.	.	.	.	8	8.5	.	.
		30-34	71	.	.	.	.	3	4.3	.	.
		35+	43	.	.	.	.	9	20.9	.	.
	Years since diagnosis	5-9	42	.	.	.	.	6	14.3	.	.
		10-14	122	.	.	.	.	16	13.1	.	.
		15-19	98	.	.	.	.	6	6.2	.	.
		20+	70	.	.	.	.	7	10.0	.	.
	Age at diagnosis	<1	2	.	.	.	.	.	.	.	.
		1-4	24	.	.	.	.	2	8.3	.	.
		5-9	86	.	.	.	.	4	4.7	.	.
		10-14	122	.	.	.	.	14	11.5	.	.
		15-20	98	.	.	.	.	15	15.5	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Adenine Arabinoside		5-Azacytidine		Cytosine Arabinoside		5-FU (5-Fluorouracil)	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1154**	**1**	**0.1**	**.**	**.**	**2**	**0.2**	**2**	**0.2**
	Age at baseline	<18	25	.	.	.	.	.	.	.	.
		18-19	27	.	.	.	.	.	.	.	.
		20-24	184	.	.	.	.	1	0.5	.	.
		25-29	317	.	.	.	.	.	.	.	.
		30-34	340	1	0.3	.	.	1	0.3	1	0.3
		35+	261	.	.	.	.	.	.	1	0.4
	Years since diagnosis	5-9	119	.	.	.	.	.	.	.	.
		10-14	362	.	.	.	.	1	0.3	.	.
		15-19	392	1	0.3	.	.	1	0.3	1	0.3
		20+	281	.	.	.	.	.	.	1	0.4
	Age at diagnosis	1-4	21	.	.	.	.	.	.	.	.
		5-9	151	.	.	.	.	.	.	.	.
		10-14	492	.	.	.	.	2	0.4	.	.
		15-20	490	1	0.2	.	.	.	.	2	0.4
Males	**All cases**		**581**	**.**	**.**	**.**	**.**	**1**	**0.2**	**2**	**0.3**
	Age at baseline	<18	18	.	.	.	.	.	.	.	.
		18-19	12	.	.	.	.	.	.	.	.
		20-24	86	.	.	.	.	1	1.2	.	.
		25-29	165	.	.	.	.	.	.	.	.
		30-34	161	.	.	.	.	.	.	1	0.6
		35+	139	.	.	.	.	.	.	1	0.7
	Years since diagnosis	5-9	64	.	.	.	.	.	.	.	.
		10-14	191	.	.	.	.	1	0.5	.	.
		15-19	192	.	.	.	.	.	.	1	0.5
		20+	134	.	.	.	.	.	.	1	0.8
	Age at diagnosis	1-4	11	.	.	.	.	.	.	.	.
		5-9	76	.	.	.	.	.	.	.	.
		10-14	221	.	.	.	.	1	0.5	.	.
		15-20	273	.	.	.	.	.	.	2	0.7
Females	**All cases**		**573**	**1**	**0.2**	**.**	**.**	**1**	**0.2**	**.**	**.**
	Age at baseline	<18	7	.	.	.	.	.	.	.	.
		18-19	15	.	.	.	.	.	.	.	.
		20-24	98	.	.	.	.	.	.	.	.
		25-29	152	.	.	.	.	.	.	.	.
		30-34	179	1	0.6	.	.	1	0.6	.	.
		35+	122	.	.	.	.	.	.	.	.
	Years since diagnosis	5-9	55	.	.	.	.	.	.	.	.
		10-14	171	.	.	.	.	.	.	.	.
		15-19	200	1	0.5	.	.	1	0.5	.	.
		20+	147	.	.	.	.	.	.	.	.
	Age at diagnosis	1-4	10	.	.	.	.	.	.	.	.
		5-9	75	.	.	.	.	.	.	.	.
		10-14	271	.	.	.	.	1	0.4	.	.
		15-20	217	1	0.5	.	.	.	.	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.

				Fludarabine phosphate		6-Mercaptopurine		Methotrexate		6-Thioguanine	
			All cases	N	%	N	%	N	%	N	%
Both sexes	**All cases**		**1154**	**1**	**0.1**	**.**	**.**	**900**	**78.7**	**.**	**.**
	Age at baseline	<18	25	.	.	.	.	21	84.0	.	.
		18-19	27	.	.	.	.	23	85.2	.	.
		20-24	184	.	.	.	.	161	87.5	.	.
		25-29	317	.	.	.	.	250	80.4	.	.
		30-34	340	1	0.3	.	.	270	79.6	.	.
		35+	261	.	.	.	.	175	68.1	.	.
	Years since diagnosis	5-9	119	.	.	.	.	102	85.7	.	.
		10-14	362	.	.	.	.	281	78.7	.	.
		15-19	392	1	0.3	.	.	323	82.8	.	.
		20+	281	.	.	.	.	194	70.0	.	.
	Age at diagnosis	1-4	21	.	.	.	.	19	90.5	.	.
		5-9	151	.	.	.	.	122	81.3	.	.
		10-14	492	1	0.2	.	.	403	82.6	.	.
		15-20	490	.	.	.	.	356	73.6	.	.
Males	**All cases**		**581**	**.**	**.**	**.**	**.**	**467**	**81.2**	**.**	**.**
	Age at baseline	<18	18	.	.	.	.	15	83.3	.	.
		18-19	12	.	.	.	.	11	91.7	.	.
		20-24	86	.	.	.	.	71	82.6	.	.
		25-29	165	.	.	.	.	132	82.0	.	.
		30-34	161	.	.	.	.	134	83.8	.	.
		35+	139	.	.	.	.	104	75.4	.	.
	Years since diagnosis	5-9	64	.	.	.	.	52	81.3	.	.
		10-14	191	.	.	.	.	149	79.3	.	.
		15-19	192	.	.	.	.	165	86.4	.	.
		20+	134	.	.	.	.	101	76.5	.	.
	Age at diagnosis	1-4	11	.	.	.	.	10	90.9	.	.
		5-9	76	.	.	.	.	62	82.7	.	.
		10-14	221	.	.	.	.	185	84.5	.	.
		15-20	273	.	.	.	.	210	77.8	.	.
Females	**All cases**		**573**	**1**	**0.2**	**.**	**.**	**433**	**76.2**	**.**	**.**
	Age at baseline	<18	7	.	.	.	.	6	85.7	.	.
		18-19	15	.	.	.	.	12	80.0	.	.
		20-24	98	.	.	.	.	90	91.8	.	.
		25-29	152	.	.	.	.	118	78.7	.	.
		30-34	179	1	0.6	.	.	136	76.0	.	.
		35+	122	.	.	.	.	71	59.7	.	.
	Years since diagnosis	5-9	55	.	.	.	.	50	90.9	.	.
		10-14	171	.	.	.	.	132	78.1	.	.
		15-19	200	1	0.5	.	.	158	79.4	.	.
		20+	147	.	.	.	.	93	64.1	.	.
	Age at diagnosis	1-4	10	.	.	.	.	9	90.0	.	.
		5-9	75	.	.	.	.	60	80.0	.	.
		10-14	271	1	0.4	.	.	218	81.0	.	.
		15-20	217	.	.	.	.	146	68.2	.	.

CCSS data from the March 2026 freeze; % based on nonmissing values.
Participants had medical record abstraction, a completed baseline questionnaire, and treatment within 5 years of diagnosis.
Drugs with unclear pre-entry start dates were excluded.